

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)




PCT

(10) International Publication Number
WO 01/97608 A2

- (51) International Patent Classification⁷: **A01K 67/033**
- (21) International Application Number: PCT/EP01/06797
- (22) International Filing Date: 15 June 2001 (15.06.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
00112880.0 19 June 2000 (19.06.2000) EP
01110554.1 30 April 2001 (30.04.2001) EP
- (71) Applicant (for all designated States except US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Postfach 200, 55216 Ingelheim am Rhein (DE).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **GLOTZER, Michael** [US/AT]; Waaggasse 10/8, A-1040 Wien (AT). **JANTSCH-PLUNGER, Verena** [AT/AT]; Mühlgasse 22/6, A-1040 Wien (AT). **ROMANO, Alper** [TR/AT]; Gerlgasse 22/2/45, A-1030 Wien (AT). **MISHIMA, Masanori** [JP/AT]; Aufhofstrasse 194/1/8, A-1130 Wien (AT). **KAITNA, Susanne** [AT/AT]; Anton Baumgartnerstrasse 44 C3/16/1, A-1230 Wien (AT).
- (74) Agents: **LAUDIEN, Dieter**; c/o Boehringer Ingelheim GmbH, 55216 Ingelheim am Rhein et al. (DE).
- (81) Designated States (national): AE, AU, BG, BR, CA, CN, CO, CZ, EE, HR, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RO, SG, SK, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,

[Continued on next page]

(54) Title: CYK-4 POLYPEPTIDES, DNA MOLECULES ENCODING THEM AND THEIR USE IN SCREENING METHODS



Zen-4/CeMklp1
homodimer



Cyk-4

(57) Abstract: Mammalian CYK-4 polypeptides, which are key molecules required for cytokinesis, and DNA molecules encoding them. Screening methods based on biochemical reactions relevant for the function of CYK-4 can be employed to identify compounds interfering with cell division. Such compounds are useful in tumour therapy.

WO 01/97608 A2



CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished
upon receipt of that report*

Cyk-4 polypeptides, DNA molecules encoding them and their use in screening methods

- 5 The present invention relates to a new protein Cyk-4, which is involved in cytokinesis, to its use in screening assays, and to therapies interfering with cell division, in particular tumor therapy.

The process of cytokinesis produces two daughter cells
10 from a single parental cell and permanently segregates the products of the cell division cycle. Cytokinesis is one of the few processes in biology known to require coordination between microtubules and actin filaments. Indeed, in animal cells there are two steps in
15 cytokinesis that rely on interactions between microtubules and the actin-based contractile ring (for review see (Field et al., 1999; Glotzer, 1997). In the first instance, the microtubule-based mitotic spindle specifies the position of the contractile ring. This
20 allows the division plane to be positioned so that the separated chromosomes are partitioned equally into the two daughter cells. Subsequently, after ingression of the cleavage furrow, there is a second step that depends on both microtubules and the contractile ring.
25 Completion of cytokinesis requires the central spindle, which contains bundled, antiparallel microtubules. The molecular mechanisms underlying these two microtubule dependent steps in cytokinesis are not known.

The degree to which the progression of cytokinesis depends on the central spindle varies somewhat in different experimental organisms. In invertebrate embryos, a transient interaction between astral
5 microtubules of the mitotic spindle and the cell cortex is sufficient to position the cleavage furrow (Rappaport, 1985). Furrows specified in this manner ingress, but if the spindle is removed, these furrows do not usually complete cytokinesis (Rappaport, 1985).
10 In contrast, in *Drosophila* spermatocytes, contractile ring formation requires the central spindle (Giansanti et al., 1998). Similarly, in cultured mammalian cells, astral microtubules appear to be insufficient to induce furrow ingression, instead the presence or absence of a
15 central spindle determines whether or not a cleavage furrow forms (Cao and Wang, 1996; Eckley et al., 1997; Rieder et al., 1997; Savoian et al., 1999; Wheatley and Wang, 1996). Moreover, in cultured cells, the central spindle is also required for completion of cytokinesis
20 (Wheatley and Wang, 1996). In *C. elegans* embryos, as in invertebrate embryos, only the later stages of cytokinesis appear to depend on the central spindle. Embryos depleted of the kinesin-like protein ZEN-4/CeMKlp1 fail to assemble the central spindle, yet
25 cleavage furrows form and ingress, but cytokinesis does not proceed to completion (Powers et al., 1998; Raich et al., 1998). In summary, the initiation of cytokinesis depends on the central spindle in some but
30 not in all organisms, whereas there appears to be a general requirement for the central spindle for the completion of cytokinesis in animal cells. While it is clear that the central spindle plays an important role

in cytokinesis the underlying mechanism remains elusive.

Cleavage furrow ingression is driven by the actin-based contractile ring. Like many actin-based structures, the contractile ring requires the RhoA GTPase for its assembly. Rho family GTPases are thought to act as molecular switches that cycle between inactive GDP-bound forms and active GTP-bound forms; their ability to exchange and hydrolyze GTP is regulated by additional factors, the so-called guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Inactivation of RhoA by the exoenzyme C3 (Aktories and Hall, 1989), inhibits cytokinesis in a wide variety of experimental settings by causing disassembly of cortical actin structures and the contractile ring (Drechsel et al., 1997; Kishi et al., 1993; Mabuchi et al., 1993; Moorman et al., 1996; O'Connell et al., 1999). Further, a Rho GEF is essential for cytokinesis (Prokopenko et al., 1999; Tatsumoto et al., 1999). GTP-bound RhoA interacts with a number of putative effectors including formins, Rho Kinase, Citron kinase, and a regulatory subunit of myosin phosphatase (for review see (Van Aelst and D'Souza-Schorey, 1997). The requirement for RhoA in cytokinesis may reflect its ability to regulate formins since members of the formin gene family are required for cytokinesis in budding yeast (BNI1/BNR1) (Imamura et al., 1997), fission yeast (Cdc12) (Chang et al., 1997), *Drosophila* (*dia*) (Castrillon and Wasserman, 1994) and *C. elegans* (*cyk-1*) (Swan et al., 1998). Several formins also bind to profilin (Chang et al., 1997 ; Evangelista et al., 1997; Imamura et al., 1997;

Watanabe et al., 1997), a key regulator of actin polymerization. It is conceivable that GTP-bound RhoA promotes contractile ring assembly by activating actin polymerization via the formins and by activating myosin motor activity.

There is compelling evidence that the microtubule-based central spindle and the actin-based cleavage furrow are both essential for cytokinesis. Next, the question was asked how these two cytoskeletal polymers interact.

There are a few cases in which an interaction between the microtubule and actin cytoskeletal systems have been characterized. Examples include nuclear positioning in budding yeast (Carminati and Stearns, 1997; Fujiwara et al., 1999; Miller et al., 1999), spindle orientation in epithelial cells (Busson et al., 1998) and in certain asymmetrically dividing cells, such as the posterior blastomere of the two cell *C. elegans* embryo (Gönczy et al., 1999a; Hyman and White, 1987; Skop and White, 1998; Waddle et al., 1994). In these examples there is evidence that the dynein/dynactin microtubule motor complex may mediate the interaction of microtubules with the cell cortex.

It was an object of the invention to elucidate the microtubule dependent steps in cytokinesis. In particular, it was sought to define the role of the central spindle in this process, in order to be able to interfere with this process and thus with cytokinesis, which provides a new approach for therapy, in particular cancer therapy.

Therefore, to solve the problem underlying the invention, it was investigated how the central spindle assembles and how it functions in cytokinesis.

In the present invention, a novel gene designated *cyk-4* was identified and cloned and its role in the early divisions of the *C. elegans* embryo was characterized. It was shown that Cyk-4 is required for the late stages of cytokinesis. Interestingly, *cyk-4* mutant embryos fail to assemble the central spindle. Positional cloning and localization studies revealed that the *cyk-4* gene encodes a novel GTPase activating protein (GAP) for the Rho family of GTPases that localizes to the central spindle. The missense mutation in the *cyk-4(t1689ts)* allele is found in a domain dispensable for GAP activity suggesting that Cyk-4 may have another function in addition to activating GTP hydrolysis by Rho family proteins. Accordingly, it was found that Cyk-4 and the kinesin-like protein Zen-4/CeMKlp1 are interdependent for their proper localization. Based on these data, a model is proposed by which Cyk-4 acts in concert with Zen-4/CeMKlp1 to assemble the central spindle. The concentration of Cyk-4 to the central spindle would then serve to target the GAP domain to the fully ingressed contractile ring where it could promote GTP hydrolysis by RhoA, thereby facilitating the completion of cytokinesis.

In further experiments, the biochemical state of CYK-4 and ZEN-4 has been examined and it was found that they do indeed associate in vivo. These proteins also efficiently associate in vitro and an in vitro binding assay has been used to molecularly dissect the regions

of both proteins that are necessary and sufficient for this interaction. It is shown that the protein encoded by the *ts* allele *cyk-4(t1689)* is defective in binding to ZEN-4. The identification of mutations in *zen-4* that partially rescue *cyk-4(t1689)* and map to the CYK-4 binding region provides strong evidence for the importance of the interaction between CYK-4 and ZEN-4 for progression of cytokinesis. It has also been shown that the human orthologs of CYK-4 and ZEN-4, HsCYK-4/MgcRacGAP and MKLP1, are in a complex which has been purified. The complex contains approximately stoichiometric amounts of HsCYK-4 and MKLP1. The human complex localizes to the central spindle and to division remnants, as do the nematode proteins. Thus, in the present invention, an evolutionarily conserved complex that is essential for central spindle assembly has been identified.

The division of a cell into two daughters requires dynamic interactions between the microtubule-based mitotic spindle and the actin-based contractile ring. In animal cells the position of the cleavage furrow, an actomyosin-based structure, is determined by the mitotic spindle in a manner that is poorly understood. In recent years it has become clear that the central spindle, an array of microtubule bundles that forms during anaphase, also plays an important role in cytokinesis. To gain insight into this fundamental cellular process, the cytokinesis-defective mutant, *cyk-4*, was analyzed. Cytological analysis reveals that *cyk-4* mutant embryos fail to assemble the central

spindle. Though lacking a central spindle, *cyk-4* mutant embryos furrow extensively, but they fail to complete cytokinesis. The mutation responsible for the *cyk-4* phenotype was found to be a missense mutation in a gene encoding a Rho family GAP that, in vitro, stimulates GTP hydrolysis by Rho, Rac, and Cdc42. CYK-4 localizes to the central spindle and to cell division remnants. CYK-4 colocalizes with the ZEN-4/CeMKLP1 kinesin-like protein. Moreover, CYK-4 and ZEN-4/CeMKLP1 are interdependent for their localization. It is concluded that the CYK-4 GAP and the ZEN-4/CeMKLP1 kinesin-like protein cooperate to assemble the central spindle. Furthermore, it is proposed that a concentrated source of CYK-4 GAP on the central spindle could downregulate the RhoA GTPase and thereby promote the late stages of cytokinesis. The findings of the present invention provide a model for CYK-4 dependent assembly of the central spindle:

In *cyk-4* mutant embryos the robust microtubule bundles that constitute the central spindle do not form. Instead, the spindle develops into two mitotic asters separated by a few overlapping, disorganized, microtubules. A similar phenotype is observed in *zen-4* mutant embryos (Powers et al., 1998; Raich et al., 1998). Thus both the ZEN-4/CeMKLP1 kinesin-like protein and the CYK-4 GAP are essential for this microtubule bundling. The *Drosophila* orthologue of ZEN-4/CeMKLP1 is also required for cytokinesis, though it seems to be required for all aspects of furrow ingression (Adams et al., 1998). Members of the MKLP1 subfamily of kinesin-like proteins have microtubule bundling activity in

vitro (Kuriyama et al., 1994; Nislow et al., 1992). However, *in vivo*, ZEN-4 mediated microtubule bundling requires CYK-4.

In answering the question how CYK-4 and ZEN-4 could
5 cooperate to assemble the central spindle, it is proposed that a complex containing multiple motor proteins could specifically localize to overlapping, antiparallel microtubules (figure 10). If such a motor complex transits along a microtubule it might continue
10 to an end and dissociate. However, if such a motor complex transited along a microtubule in the vicinity of an antiparallel microtubule, the complex might bind simultaneously to both microtubules and attempt to move alternately in opposite directions, the net result
15 being that the complex would concentrate in the region of microtubule overlap. Since CYK-4 does not have a microtubule motor domain, yet it is essential for the formation of the central spindle, it is proposed that CYK-4 forms a complex with multiple ZEN-4 homodimers
20 that localizes to and stabilizes overlapping antiparallel microtubules (figure 10).

It was of interest to find out if the RhoGAP activity of CYK-4 necessary to promote microtubule bundling by ZEN-4. It is proposed that central spindle assembly is
25 unlikely to require CYK-4 GAP activity. This is suggested by two lines of evidence. First, central spindle assembly is defective in the *cyk-4(t1689ts)* allele that carries a missense mutation at amino acid 15. This substitution is distant from the
30 C-terminal GAP domain, and *in vitro*, the amino terminus of CYK-4 is dispensable for GAP activity. Thus this

allele would be predicted to retain catalytic activity *in vivo* and therefore GAP activity is not sufficient for central spindle assembly. Moreover, Rho RNAi experiments reveal that central spindle assembly is Rho
5 independent, suggesting that Rho GAP activity is not required for this process. Thus CYK-4 may act to promote central spindle assembly, independent of its GAP activity.

In the present invention, the function of the CYK-4 gap
10 domain was analysed:

If CYK-4 function in central spindle assembly is independent of the Rho GTPase, it was of interest to determine the function of the CYK-4 GAP domain. CYK-4 is likely bifunctional, one function being to promote
15 the assembly of the central spindle, the second function being to promote GTP hydrolysis by Rho family members. These two functions might be related in that the first function would serve to concentrate CYK-4 at a site where GAP activity is required. It may be
20 assumed that CYK-4 GAP activity is required late in cytokinesis, to promote GTP hydrolysis by a Rho family GTPase whose downregulation causes disassembly of the contractile ring and cell separation (fig. 10).

It was determined which GTPase might CYK-4 act on to
25 promote cytokinesis. The CYK-4 GAP domain has all the hallmarks of a Rho family GAP and it may therefore be expected that it will act on this subfamily of the GTPase superfamily. Like many other RhoGAPs, the GAP domain of CYK-4 is promiscuous in its ability to
30 promote GTP hydrolysis on Rho, Rac, and Cdc42 (Lamarche

and Hall, 1994). The strongest piece of evidence that CYK-4 acts on Rho is based on the observation that of the GTPases tested, Rho is the only one that is clearly essential for cytokinesis. The requirement for Rho in
5 cell division is well documented in a variety of experimental systems. To date there is no evidence that Rac is required for cytokinesis and the data using RNAi to deplete Rac also failed to detect a role for this GTPase in this process. Moreover, it has been recently
10 reported that *ced-10* mutants, which are defective in corpse engulfment subsequent to apoptosis and distal tip cell migration, contain mutations in the *rac* gene (Reddien and Horvitz, 2000). *ced-10* mutants do not have any gross phenotypes indicative of a role in
15 cytokinesis. Moreover, *Rac1* deficient mice are gastrulation defective, but the embryos do not contain multinucleate cells indicative of a cell division defect (Sugihara et al., 1998). The sum of these data argue that Rac is not an essential target of CYK-4
20 during cytokinesis. With regard to *Cdc42*, previous studies have implicated this GTPase in cytokinesis (Drechsel et al., 1997; Dutartre et al., 1996). Superficially, the weakly penetrant cytokinesis phenotype observed in *Cdc42(RNAi)* embryos is consistent
25 with these earlier data. However the *Cdc42(RNAi)* embryos that are cytokinesis defective are also osmotically swollen and therefore cytokinesis defect may be indirect. Thus at this juncture it appears most likely that RhoA is the key substrate for the CYK-4 GAP
30 activity.

Further support for the hypothesis that completion of cytokinesis requires downregulation of RhoA by CYK-4

would be supported by experiments in which the *cyk-4* phenotype is phenocopied by RhoA mutants that are hydrolysis defective. However the genetic tools necessary to express such dominant mutants in the early
5 *C. elegans* embryo are currently unavailable. It is surprising that the CYK-4 GAP domain is less active towards RhoA as compared to Rac or Cdc42, if indeed RhoA is the relevant target of its GAP activity. One possible explanation is that full length CYK-4 has a
10 different activity profile as compared to the isolated GAP domain. A more interesting possibility is that CYK-4 localization is important for CYK-4 GAP activity. The phenotype of *cyk-4* mutant embryos suggests that CYK-4 needs to act when the contractile ring is in
15 close proximity to the central spindle. Since CYK-4 is concentrated on the central spindle at this time, its high local concentration might overcome its lower activity towards RhoA.

In the present invention, the central spindle was shown
20 to be at the center of cytokinesis:

There appear to be at least two microtubule-dependent steps in cytokinesis, contractile ring positioning and completion of cytokinesis. In some cells both processes are dependent on the central spindle. An
25 important open question is whether these two reactions are mechanistically similar. While assembly of the contractile ring requires activation of RhoA, it was previously shown that the position of the contractile ring is specified in a RhoA-independent manner in
30 *Xenopus* embryos (Drechsel et al., 1997). It has been shown here that a Rho GAP is required for the late

stages of cytokinesis, suggesting that the second process, completion of cytokinesis, does involve RhoA. It is therefore assumed that the two microtubule-dependent steps in cytokinesis are distinct.

5 CYK-4 and ZEN-4 are not the only components of the central spindle, a number of other components, some of which are required for cytokinesis, are also present at this site. Polo kinase is known to associate with MKLP1 and to concentrate in the central spindle (Adams et
10 al., 1998; Lee et al., 1995), and this kinase is essential for cytokinesis. Rho associated kinase also localizes to this site (Kosako et al., 1999). The AIR-2 aurora-like kinase localizes to the central spindle (Schumacher et al., 1998). This kinase seems to be
15 required primarily for chromosome segregation (Woollard and Hodgkin, 1999), its direct involvement in cytokinesis requires further analysis. INCENP and the TD-60 antigen also localize to the central spindle and there is evidence that they may play a role in
20 cytokinesis (Eckley et al., 1997; Mackay et al., 1998; Martineau-Thuillier et al., 1998; Savoian et al., 1999). Interestingly, a Rho GEF that is required for cytokinesis, ECT2, also accumulates on the central spindle (Tatsumoto et al., 1999), however the
25 *Drosophila* ortholog, Pebble, does not localize in this manner (Prokopenko et al., 1999).

Further analysis of the specific functions of all of these cytokinesis regulators is the basis to determine which of these proteins are functionally interdependent
30 as has been shown is the case for Cyk-4 and Zen-4/CeMKlp1.

Furthermore, it was shown that the central spindle is a structure that is essential for completion of cytokinesis. Two proteins required for central spindle assembly, CYK-4 and ZEN-4, were shown to co-localize to the central spindle and to somehow act in concert with one another. In experiments of the present invention, it was demonstrated that in vivo, CYK-4 and ZEN-4 are present in an evolutionarily conserved protein complex and the nature of this complex in *C. elegans* embryos and in human cells was characterized in detail. These data suggest that the CYK-4/ZEN-4 complex, which was named centralspindlin, consists of a two molecules each of CYK-4 and ZEN-4. CYK-4 binds to the neck region of the ZEN-4 kinesin, raising the possibility that the motor activity of the ZEN-4 is directly regulated by the CYK-4 RhoGAP.

Analytical biochemistry of the native centralspindlin complex isolated from *C. elegans* embryos demonstrates the existence of a complex containing the ZEN-4 kinesin and the CYK-4 RhoGAP. In vitro binding experiments were used to define the critical determinants for this interaction and to demonstrate that the two subunits are able to self associate. Genetic and biochemical suppression of the CYK-4 S15L mutation by a second site mutation in ZEN-4 strongly argues that the interaction between CYK-4 and ZEN-4 is critical for CYK-4 function. Indeed, in vivo, the majority of ZEN-4 is in a complex with CYK-4. Moreover, three lines of evidence indicate that HsCYK-4 and MKLP1 are in a tetrameric complex. First, immunopurification of HsCYK-4 and MKLP1 reveals equal amounts of the two proteins. Second, these two proteins co-migrate on sucrose density gradients with a

similar S value as observed for the *C. elegans* proteins. Third, the two proteins precisely co-migrate on a gel filtration column and their fractionation behavior suggests a native molecular mass for the
5 complex of ~300 kDa. Previous determinations of the native molecular mass of MKLP1 have been reported and the values are similar to those obtained in the present invention here (Chui et al., 2000; Kuriyama et al., 1994). Previous studies had not taken the presence of
10 CYK-4 into consideration and therefore they interpreted their data to indicate that MKLP1 exists as a homotetramer. However, the data obtained in the experiments of the invention are not compatible with this interpretation, but they rather indicate that the
15 centralspindlin complex is a tetramer containing two molecules of the kinesin ZEN-4/MKLP1 and two molecules of the RhoGAP CYK-4.

CYK-4 binds to ZEN-4 in a particularly interesting region of this kinesin family member. Rice et al., 1999
20 have established that a critical element of the kinesin molecule lies just C-terminal to the catalytic core; the neck linker region. ATP binding to one catalytic core induces a large scale conformational change in the neck linker region that causes the other catalytic core
25 to extend towards the adjacent tubulin dimer situated on the plus side of the initial microtubule contact (Rice et al., 1999). In the present invention, it was found that CYK-4 binds to a region of ZEN-4 that includes the neck linker region. In conventional
30 kinesin, the neck linker region corresponds to a region 15 amino acids long that connects the catalytic core of kinesin to the coiled coil stalk domain. Among the

family of KIN-N motors, the MKLP1 subfamily has a distinctly divergent neck linker region, it lacks several nearly invariant residues and the linker between the catalytic core and the coiled coil region is about 5 times longer than in other members on the KIN-N family. The divergence of this critical region of the kinesin suggests that MKLP1-mediated microtubule motility may differ from that of other kinesins. Moreover, since CYK-4 binds to the neck linker region of ZEN-4 it is possible that CYK-4 binding may in fact regulate ZEN-4 motor activity.

Previous work had suggested that MKLP1 may exist as a tetramer containing 4 motor domains (Chui et al., 2000; Kuriyama et al., 1994). If the two dimers were arranged in an antiparallel orientation, this arrangement could easily explain how this complex could crosslink antiparallel microtubules. However, the data obtained in the present invention are not consistent with this proposed structure. The complex that has been characterized appears to contain two kinesin motors and two RhoGAP molecules. Since most kinesin motors are dimers in which both catalytic cores interact with a single microtubule protofilament, the architecture that is described here can not easily explain how microtubule bundling is achieved. If the two kinesin subunits of centralspindlin bind to the same microtubule protofilament, then how might microtubule crosslinking occur? At this point, at least three possible mechanisms can be envisaged (fig. 18).

The first possibility is that there is an additional microtubule binding site elsewhere in the CYK-4/ZEN-4

complex. No additional binding site has been identified yet in CYK-4 nor has MKLP1, ZEN-4, or Pav been found to have an additional microtubule binding site. However, it has been shown, and was confirmed by
5 the inventors, that MKLP1 interacts differently with microtubules than most kinesin-like proteins. Specifically, ATP is usually sufficient to elute most kinesins from microtubules, but in the case of MKLP1, both ATP and high salt are required (Kuriyama et al.,
10 1994; Nislow et al., 1992). Thus it is possible that MKLP1 interacts with two microtubules, one by the motor domain and another via a different interaction surface. Consistent with this possibility is the finding that Rab6KIFL kinesin, which is quite similar to MKLP1 in
15 primary structure as well as in its localization and proposed function (Fontijn et al., 2001; Hill et al., 2000), has been reported to contain a second microtubule binding activity in the C-terminal half of the molecule (Echard et al., 1998). However this
20 possibility does not explain why CYK-4 is required for central spindle assembly.

The second alternative is that MKLP1 forms higher order structures and that the tetramer that has been characterized in the present invention is merely a
25 building block. This possibility gains some support from localization studies. In both *C. elegans* and in mammalian cells, ring-like structures are found that are termed division remnants that persist in the cell cortex after division. These remnants appear to be
30 large aggregates of centralspindlin which are not in direct association with microtubules. Higher order

oligomers could potentially form in early anaphase and promote microtubule bundling.

The third possibility is that, unlike most N-terminal kinesins, the two catalytic cores of the kinesin subunits in the centralspindlin complex could bind to different microtubules. This would not be without precedent in that the KIN-N KIF1A moves processively along a microtubule using a single head (Okada and Hirokawa, 2000). The association of the two catalytic cores of MKLP1 with different microtubules is made feasible by the fact that the linker region between the catalytic core and the coiled coil domain is much longer than that present in most N-terminal kinesins. Perhaps CYK-4 ensures that the two motor domains are oriented in such a way to bind to antiparallel microtubules (fig 18). Structural analysis and biochemical reconstitution of centralspindlin from purified components will allow further insight into mechanism of antiparallel microtubule bundling.

One critical question, which has not been rigorously explored to date is the function of the central spindle during the process of cytokinesis. The obtained data do not shed extensive new light on this question. However, it may be noted that the RhoGAP domain of CYK-4 is highly conserved at the primary sequence level. Interestingly CYK-4 is significantly less active at inducing GTP hydrolysis by RhoA as compared to Rac and Cdc42 (Jantsch-Plunger et al., 2000), and this feature of CYK-4 is conserved in HsCYK-4 (Toure et al., 1998). It has been proposed by the inventors that one function of the central spindle is to concentrate

CYK-4 to a position in the cell where it could promote inactivation of RhoA at a late stage in cytokinesis. Consistent with this model, inactivation of RhoA by RNAi does not prevent CYK-4 localization nor does it
5 impair central spindle assembly. In addition, the RhoGAP domain seems to be required at some stage of cytokinesis, since overexpression of a HsCYK-4/MgcRacGAP bearing a mutation in the RhoGAP domain causes cytokinesis defects (Hirose et al., 2001).
10 Further structure-function analysis of CYK-4 is necessary to test this model further. However such analyses must take into consideration that CYK-4 is able to dimerize or oligomerize and therefore such analysis is best done in the absence of endogenous
15 CYK-4.

Although centralspindlin appears to be a simple tetrameric complex, there are several lines of evidence that suggest that it may be subject to regulation by at least two different kinases. Genetic analysis of Polo
20 kinase in *Drosophila* indicates Pav localization is Polo dependent (Carmena et al., 1998) and moreover a biochemical interaction between Polo and MKLP1 orthologs have been shown in extracts from both mammalian cell and *Drosophila* embryos (Adams et al.,
25 1998; Lee et al., 1995). In addition, the Aurora-B/Incenp complex is also required for the stable localization of centralspindlin in *C. elegans* embryos (Kaitna et al., 2000; Schumacher et al., 1998; Severson et al., 2000) and an in vitro biochemical interaction
30 has been detected between Aurora-B (AIR-2) and ZEN-4 (Severson et al., 2000).

A stable association between Polo kinase or Aurora-B kinase with centralspindlin has not been observed. Reconstitution of central spindle assembly in vitro will allow the role of these and other regulators of centralspindlin to be dissected.

In summary, the experiments of the present invention comprise an initial phenotypic, molecular, biochemical, and cell biological analysis of the *cyk-4* gene. Furthermore, they comprise an analysis of the CYK-4/ZEN-4 complex (centralspindlin) that consists of two molecules of each CYK-4 and ZEN-4.

The experiments of the present invention (Examples 1-5) indicate that Cyk-4 is an active GTPase activating protein that is required for cytokinesis, likely by its ability to regulate the RhoA GTPase. Quite surprisingly, one additional function of this protein is to promote assembly of the central spindle. Cyk-4 is a key molecule required for cytokinesis that regulates both the structure of the late mitotic spindle and the function of the contractile ring.

Thus, in a first aspect, the present invention generally relates to Cyk-4 polypeptides, which have been shown to be essential for this second microtubule dependent step and thus define a functional link between the central spindle and the contractile ring.

In a preferred embodiment, the invention relates to a mammalian Cyk-4 polypeptide, in particular murine and human Cyk-4.

In a first aspect, the invention relates to the murine Cyk-4 polypeptide with the amino acid sequence as set forth in SEQ ID NO:4 or with the amino acid sequence encoded by a polynucleotide which hybridizes under
5 stringent conditions to a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO:3.

In a preferred aspect, the invention relates to the human Cyk-4 polypeptide with the amino acid sequence as set forth in SEQ ID NO:2 or with the amino acid
10 sequence encoded by a polynucleotide which hybridizes under stringent conditions to a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO:1.

In a further aspect, the present invention relates to an isolated DNA molecule comprising a polynucleotide
15 with the nucleotide sequence as set forth in SEQ ID NO:1 encoding human Cyk-4 polypeptide, or an isolated DNA molecule encoding human Cyk-4 polypeptide comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide having a
20 nucleotide sequence as set forth in SEQ ID NO:1.

In a further aspect, the present invention relates to an isolated DNA molecule comprising a polynucleotide with the nucleotide sequence as set forth in SEQ ID NO:3 encoding murine Cyk-4 polypeptide, or an isolated
25 DNA molecule encoding murine Cyk-4 polypeptide comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO:3.

By "stringent hybridization conditions" as used herein
30 is meant overnight incubation at 42°C in a solution

comprising: 50% formamide, 5x SSC (1X SSC = 150 mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA,
5 followed by washing the filters in 0.1x SSC at about 65°C, or equivalent conditions.

In the following, if not otherwise stated, the term "Cyk-4" refers to both the murine and the human Cyk-4.

Homologues of the subject Cyk-4 polypeptides also
10 include versions of the polypeptide which are resistant to post-translation modification or which alter the activity of the protein. Cyk-4 polypeptides may comprise a full length protein, such as represented in SEQ ID NO:2 or 4, or they may comprise fragments or variants
15 thereof.

Beside DNA molecules, the present invention relates to nucleic acid molecules in the form of RNA, such as mRNA. The DNA molecules include cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA
20 may be double-stranded or single-stranded.

Single-stranded DNA or RNA may be the coding strand, also known as the sense (or plus) strand, or it may be the non-coding strand, also referred to as the antisense (or minus) strand. The present invention also
25 relates to preparations of double stranded Cyk-4 RNA or derivatives thereof that can be used to interfere with gene expression by ds-RNA mediated gene interference as described by Fire et al. 1998 and reviewed by Fire, 1999; Boshier and Labouesse, 2000; Sharp, 1999.

By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. Recombinant DNA molecules contained in a vector are considered isolated
5 for the purposes of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells, and those DNA molecules purified (partially or substantially) from a solution whether produced by
10 recombinant DNA or synthetic chemistry techniques. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. However, it is intended that "isolated" as used herein does not include the *Cyk-4* cDNA present in
15 a cDNA library or in a preparation of purified or isolated genomic DNA containing the *Cyk-4* gene or a portion thereof in admixture with one or more other cDNA molecules or DNA fragments.

The nucleic acid molecules of the present invention
20 further include genetic constructs comprising one or more *Cyk-4* DNA sequences operably linked to regulatory DNA sequences (which may be heterologous regulatory sequences), such as promoters or enhancers, wherein upon expression of these DNA sequences in host cells,
25 preferably in bacterial, fungal (including yeast), plant or animal (including insect or mammalian) cells, one or more *Cyk-4* polypeptides are produced. In such constructs, the design of which is described in laboratory manuals (see e.g. Sambrook et al., 2000) and
30 is routine to the skilled artisan, the regulatory sequences may be operably linked to a *Cyk-4* polynucleotide encoding mature *Cyk-4* polypeptide or any

- of its variants, precursors, fragments or derivatives described herein, which may include one or more polynucleotides having a nucleic acid sequence that is complementary to substantially all or a portion of a
- 5 nucleic acid molecule having a nucleic acid sequence as shown in SEQ ID NO:1 or 3. As used herein, the terms "a portion" or "a fragment" of a nucleic acid molecule or a polypeptide means a segment of a polynucleotide or a polypeptide comprising at least 15, and more preferably
- 10 at least 20, contiguous nucleotides or amino acids of a reference polynucleotide or polypeptide (for example, the polynucleotide and polypeptide shown in SEQ ID NOs: 1 or 3, respectively, unless otherwise specifically defined below.)
- 15 Besides the DNA molecules having a nucleotide sequence corresponding to that depicted SEQ ID NO:1 or 3, the invention also relates to DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic
- 20 code, still encode the Cyk-4 mouse or human polypeptides. Since the genetic code is well known in the art, it is routine for one of ordinary skill in the art to produce the degenerate variants described above without undue experimentation.
- 25 In addition, the invention relates to Cyk-4 polypeptides which have deviations from the sequence shown in SEQ ID NO:2 or 4, caused by the conservative exchange of amino acids, if they are Cyk-4 derivatives or fragments or peptides with the properties which are
- 30 desirable for their use in therapy or in screening assays, or isolated DNA molecules encoding such

derivatitives or fragments with a polynucleotide sequence varying in their sequence from SEQ ID NO:1 or 3.

Nucleic acid molecules of the present invention which
5 encode a Cyk-4 polypeptide or a derivative or fragment thereof may include, but are not limited to, those encoding the amino acid sequence of the polypeptide by itself, together with additional, non-coding sequences, including for example introns and non-coding 5' and 3'
10 sequences, such as the transcribed, untranslated regions (UTRs) or other 5' flanking sequences that may play a role in transcription (e.g., via providing ribosome- or transcription factor-binding sites), mRNA processing (e.g. splicing and polyadenylation signals) and stability of mRNA; the coding sequence for the
15 Cyk-4 polypeptide operably linked to a regulatory DNA sequence, particularly a heterologous regulatory DNA sequence such as a promoter or enhancer; and the coding sequence for the Cyk-4 polypeptide linked to one or
20 more coding sequences which code for amino acids that provide additional functionalities. Thus, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In
25 certain embodiments of this aspect of the invention, the marker amino acid sequence may be a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described for instance in
30 Gentz et al., 1989, hexa-histidine provides for convenient purification of the fusion protein. The "HA" tag is another peptide useful for purification

which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson *et al.*, 1984. Yet another useful marker peptide for facilitation of purification of

5 Cyk-4 is glutathione S-transferase (GST) encoded by the pGEX fusion vector (see, e.g., Winnacker, *From Genes to Clones*, New York: VCH Publishers, pp. 451-481 (1987)). As discussed below, other such fusion proteins include the Cyk-4 fused to immunoglobulin Fc at the N- or

10 C-terminus.

A still further aspect of the present invention relates to antibodies and antibody preparations specifically reactive with an epitope of the Cyk-4 polypeptide.

Polyclonal antibodies are conventionally obtained by

15 immunising animals, particularly rabbits, by injecting the antigen or fragments thereof and subsequently purifying the immunoglobulin.

Monoclonal anti-Cyk-4-antibodies may be obtained by standard procedures following the principle described

20 by Köhler and Milstein, 1975, by immunising animals, particularly mice, then immortalising antibody-producing cells from the immunised animals, e.g. by fusion with myeloma cells, and screening the supernatant of the hybridomas obtained by immunological

25 standard assays for monoclonal anti- Cyk-4 -antibodies. For therapeutic or diagnostic use in humans, these animal antibodies may optionally be chimerised in the conventional way (Neuberger *et al.*, 1984, Boulianne *et al.*, 1984) or humanised (Riechmann *et al.*, 1988,

30 Graziano *et al.*, 1995).

Cyk-4 specific antibodies can be used for both diagnostic and screening applications.

Cyk-4 specific antibodies are useful in clinical situations, where determining overexpression or underexpression of CYK-4 has predictive value. Anti-CYK-4 antibodies can be used on tissue of cell specimens to evaluate the level of expression or changes in the subcellular localization in various disease states. In addition, anti-CYK-4 antibodies can be used to detect the presence of CYK-4 in solid-phase binding assays as described in the subsequent subsection related to finding compounds that affect the interaction of CYK-4 with other proteins.

In a further aspect, the present invention provides screening methods for identifying compounds capable of modulating, in particular inhibiting, cytokinesis by modulating, in particular inhibiting, the function of CYK-4.

In a first embodiment, the screening method of the invention is used to identify compounds that modulate the function CYK-4 to promote GTP hydrolysis by Rho family GTPases. (Due to the evolutionary conservation of the GTPase domain and the requirement for Rho in cytokinesis, it can be concluded from the findings of the invention that the ability of CYK-4 to promote GTP hydrolysis by Rho is crucial for CYK-4 function.)

In this embodiment of the invention, a compound's ability to promote GTP hydrolysis by a Rho family GTPase is determined by incubating a substrate selected from the members of the Rho family GTPases with GTP for

a period of time sufficient to allow saturation of the substrate's GTP binding sites, adding Cyk-4 and allowing it to react in the presence or absence of the test compound, and determining the amount of hydrolyzed
5 GTP.

This type of assay may be conducted on the basis of the so-called "GTP hydrolysis assay", which is a biochemical assay carried out according to standard protocols, as described, *inter alia*, by Self et al.,
10 1995, or by Settleman and Foster, 1995. By way of example, this assay may be carried out as follows: In a first step, the substrate is incubated with GTP that carries a radioactive label (e.g. like the commercially available γ -³²P-GTP, or an otherwise measurable, e.g. a
15 fluorescent label, as described, *inter alia*, by Hazlett et al., 1993, under conditions and for a period of time sufficient to allow saturation of GTP binding sites. Subsequently, CYK-4 is added, optionally at various concentrations of from 0 to eg 1 uM; in the presence of
20 absence of test compounds. After the appropriate time (e.g. 5 min.) the amount of GTP that has been hydrolysed is determined.

After the time required for CYK-4 stimulated GTP hydrolysis by Rho in the control reaction (absence of
25 test compound), the reaction solution may be filtered through a protein binding matrix, e.g. nitrocellulose, that is arranged in the same geometrical pattern as the original microtiter plate where the reaction took place, and the radioactivity retained in the filters,
30 or the amount of liberated free phosphate (or other label as appropriate) is quantified.

To simplify the screening assay, the Rho protein may be immobilized on a solid matrix, either via a tag that allows for binding to a suitably modified solid support, e.g. by using a biotinylated Rho protein and a streptavidin-coated microtiter plate, the solid matrix may also be in the form of beads. In the above-described assays that measure GTP hydrolysis, the Rho protein is preferably human.

By way of example, the assay may be conducted as follows: A member of the Rho family GTPases is immobilized on a solid support, e.g. a SPA (proximity scintillation assay bead) using either an epitope tag such as His6 or other similar tags. The Rho protein is loaded with radioactive ^{32}P -gamma-GTP in the presence of EDTA. Magnesium and Cyk-4 are added in the absence or presence of test compounds, incubated for various times at which point the amount of radioactivity or other suitable label remaining associated with the beads is measured. Other embodiments of the assay include using alternative labels such as fluorescent GTP or other radioisotopes and using alternative measures of GTP hydrolysis such as measuring the amount of free ^{32}P released, as described above.

Alternatively to using the full-length Rho protein, a truncated version may be used, as long the GTPase activity is maintained, e.g. a fragment that lacks the critical cysteine residue in the CaaX box at the C-terminus that is required for membrane targetting.

A number of Rho proteins are available that are suitable for use in a GTP hydrolysis assay as a

substrate, they have been cloned from various species. Preferably, they are employed as recombinant proteins.

Examples for Rho substrates that may be employed are human RhoA (Swiss Prot Primary Accession Number
5 P06749), human RhoB (Swiss Prot Primary Accession Number P01121), human RhoC (Swiss Prot Primary Accession Number P08134), human RAC1 (Swiss Prot Primary Accession Number P15154), human RAC2 (Swiss Prot Primary Accession Number P15153), human RAC3
10 (Swiss Prot Primary Accession Number O14658) and human GB25 (Swiss Prot Primary Accession Number P21181).

Based on the sequence information, the Rho substrates and the potentially present co-factor(s) can be produced recombinantly in suitable host cells, e.g. in
15 E. coli or by means of baculovirus in insect cells, according to standard methods.

Compounds that have the ability to prevent CYK-4 stimulated GTP hydrolysis by Rho family GTPases are then tested for specificity in a similar assay format
20 using other proteins that have Rho family GAP domains, e.g. p190 or RhoGAP (Lamarche and Hall, 1994).

In an alternative embodiment of the screening method, the compound's ability to inhibit Cyk-4 function is determined by determining the compound's ability to
25 interfere with the biochemical interaction of CYK-4 with a member of the MKLP1 subfamily.

The function of CYK-4 in cytokinesis is intimately tied to its ability to interact with MKLP1, a kinesin like protein that is also required for central spindle

assembly. Therefore compounds that inhibit this interaction are expected to prevent cytokinesis and to inhibit cell proliferation.

Examples for members of the MLKP1 family are CeM03D4.1b
5 (C. elegans; GenBank ID U61955, Protein ID 1397342) and
HsMKLP1 (human; GenBank ID X67155; SwissProt Q02241).
Preferably, HsMKLP1 is employed.

In C.elegans extracts, CYK-4 and CeMKLP1 are present in
a protein complex and can be co-immunoprecipitated and
10 co-purified. The nature of this protein interaction can
be further characterized, in particular by determining
whether additional proteins also interact with this
complex.

In an assay that employs an additional protein
15 component involved in this interaction, a compound's
ability to modulate Cyk-4 function is determined by
determining its effect on the interaction of said
protein with the Cyk-4/MKLP1 complex.

In carrying out an assay based on the Cyk-4/MKLP1
20 interaction, a minimal set of proteins necessary to
form a stable complex, i.e. Cyk-4, MLKP1, and
additional potential protein co-factors are produced in
recombinant form.

The domains required for the interaction of Cyk-4 and
25 MKLP1 have been identified by the present inventors.

In an embodiment of the invention, the domain of Cyk-4
that interacts with MKLP1 (i.e. the N terminal Cyk-4
region containing at least amino acids 1-120), or the

- whole Cyk-4 protein, is immobilized on a solid support, as described below. The domain of MKLP1 that interacts with CYK-4 (i.e. the central MKLP1 domain containing at least amino acids 503-603) or the whole MLKP1 protein
- 5 that is modified with a suitable label to allow for rapid detection (i.e. radiolabelled, fluorescently labeled, hapten labelled etc., as described below) is incubated in the presence or absence of the test compounds.
- 10 After an incubation period that allows for interaction of the proteins, e.g. for about 20 minutes at 25°C, the amount of MKLP1 bound to the immobilized CYK-4 is measured by use of the label outlined above or by the use of suitable antibodies in an ELISA type assay. The
- 15 assay may also be setup in the reverse, e.g. with Cyk-4 being labeled or with MKLP1 immobilized, or by performing the binding reaction in solution and then capturing one of the components on a solid support and measuring the amount of the other component that is
- 20 co-immobilized.

According to another aspect, the invention relates to a screening method that takes advantage of the biochemical multimerization of CYK-4 on the one hand and the biochemical multimerization of the MKLP1

25 subfamily of the kinesin-like protein superfamily on the other hand. This approach is based on the finding that the domain of CYK-4 that is required for interaction with MKLP1 contains a coiled-coil domain that mediates self association. Likewise the domain of

30 MKLP1 that is required to interact with CYK-4 contains a coiled-coil domain that mediates self association.

Since the ability of these proteins to self association is expected to be required for their function in vivo, compounds that inhibit the self association of either one or both of the interaction partners Cyk-4 and MKLP1
5 are candidates for perturbing cytokinesis.

In an embodiment of the invention that is based on determining whether a test compound has the ability to interfere with the self association of Cyk-4, the N-terminal domain of CYK-4 (containing at least amino
10 acids 1-120), or the whole Cyk-4 protein, is immobilized on a solid support, either directly or through a tag. (Suitable tags are commercially available, e.g. the FLAG, HA, MYC, HIS tag, etc.). Examples for solid supports useful in the present
15 invention are commercially available immunobeads or immunoplates, e.g. 96- well immunoplates, or microchips, which are coated with an antibody directed against one of the above-listed tags fused to the interacting protein.

20 A second CYK-4 fragment consisting of or containing the N terminal domain of CYK-4, i.e. amino acids 1-120, or the whole Cyk-4 protein is modified with a suitable label that allows for rapid detection. (The immobilized and the labeled Cyk-4 protein (fragments) may be
25 identical or different.)

Examples for suitable labels are commercially available radioactive or fluorescence labels, hapten labels, or peptide labels, e.g. Europium or the Green Fluorescent Protein (GFP), an enzyme label, e.g. luciferase,
30 alkaline phosphatase etc.)

The labeled Cyk-4 (fragment) is incubated with the immobilized CYK-4 in the presence or absence of the test compounds.

After an incubation period that allows for interaction
5 of the proteins, e.g. for ca. 20 min, the amount of CYK-4 bound to the immobilized CYK-4 is determined by measuring the signal of the label or by the use of suitable antibodies in an ELISA type assay.

In a further embodiment of the invention, the screening
10 method to identify modulators of Cyk-4 function is based on determining whether a test compound has the ability to interfere with the self association of MKLP1. In this embodiment, the central domain of MKLP1 (containing at least amino acids 503-603) or the whole
15 MKLP1 protein, is immobilized on a solid support.

A second MKLP1 fragment, consisting of or containing the above-defined central domain of MKLP1, or the whole MKLP1 protein is modified with a suitable label that allows for rapid detection. (The immobilized and the
20 labeled MKLP1 protein (fragments) may be identical or different).

The assay for identifying inhibitors of MKLP1 self assembly may be conducted in the the same way as described above for identifying inhibitors of Cyk-4
25 self assembly.

All embodiments of the screening methods of the invention may be performed in the high throughput format by automation of the reaction steps. In this case, a great number of compounds, e.g. from compound

or natural product libraries, are applied to microtiter plates containing the components necessary for the reaction.

- Due to their ability of inhibiting the function of
- 5 Cyk-4 to promote GTP hydrolysis by Rho family GTPase, of interfering with the interaction between Cyk-4 and MKLP1, or by interfering with self assembly of Cyk-4 and/or MKLP1, respectively, compounds identified in the above screens have the potential to perturb
- 10 cytokinesis. In tumor cells, this effect may result in a decrease or a stop of tumor growth. In addition, inhibition of cytokinesis may cause the activation of a cell cycle arrest check point that will trigger apoptosis of the tumor cells.
- 15 In light of the recent observation (Van de Putte et al 2001) that murine CYK-4 is highly expressed in Purkinje cells of the brain, in particular in cells that have abundant antiparallel bundles of microtubules (as is the case in the central spindle), it may be assumed
- 20 that compounds that inhibit CYK-4 function in cytokinesis may also impair CYK-4 function in neuronal cells. Inhibitors of CYK-4 function in these cells may have utility in the treatment of neurological disorders, e.g. neuronal hyperactivity.
- 25 Compounds that have been identified in the above-described assays to specifically affect CYK-4 function are drug candidates which may be further developed, e.g. in a first step, by structure-function analysis.

To further evaluate the potential of the compounds as

30 drugs, the candidate compounds can be assayed for their

effect on cytokinesis and other cellular processes in tissue culture of normal or transformed cells. To test the inhibition of tumor cell proliferation, primary human tumor cells, are incubated with the compound
5 identified in the screen and the inhibition of tumor cell proliferation is tested by conventional methods, e.g. bromo-desoxy-uridine or ³H thymidine incorporation.

Compounds that exhibit an anti-proliferative effect in these assays may be further tested in tumor animal
10 models and used for the therapy of tumors.

Thus, in a further aspect, the invention relates to compounds identified in the above screens for the therapy of tumors and any other situation in which cell overproliferation is observed.

15 Toxicity and therapeutic efficacy of the compounds identified as drug candidates by the screening methods of the invention can be determined by standard pharmaceutical procedures, which include conducting cell culture and animal experiments to determine the
20 IC₅₀, LD₅₀, the ED₅₀. The data obtained are used for determining the human dose range, which will also depend on the dosage form (tablets, capsules, aerosol sprays, ampules, etc.) and the administration route (oral, buccal, nasal, paterental or rectal). A
25 pharmaceutical composition containing the compound as the active ingredient can be formulated in conventional manner using one or more physiologically active carriers and excipients. Methods for making such formulations can be found in manuals, e.g. Remington Pharmaceutical

Sciences, 1980; Remington: The Science and Practice of
Pharmacy, 2000.

Brief description of the figures.

Figure 1:

- 5 *cyk-4(t1689ts)* mutant embryos fail to complete cytokinesis.

Figure 2:

cyk-4 mutant embryos produce deeply ingressing cleavage furrows, but do not form a prominent central spindle.

- 10 Figure 3:

Positional cloning of the *cyk-4* locus.

Figure 4:

cyk-4(RNAi) causes disorganization of the proximal gonad and affects formation of the central spindle.

- 15 Figure 5:

CYK-4 enhances GTP hydrolysis by Rho, Rac, and Cdc42.

Figure 6:

rho(RNAi) causes cytokinesis defects and *cdc42(RNAi)* causes defects in spindle positioning.

- 20 Figure 7:

CYK-4 localizes to the central spindle and division remnants.

Figure 8:

Time lapse analysis of CYK-4:GFP.

Figure 9:

- 5 CYK-4 and ZEN-4/CeMKLP1 colocalize and are interdependent for their localization.

Figure 10:

Model for the function of CYK-4 in central spindle formation and cytokinesis.

Figure 11:

RhoA does not have a role in the formation of central spindle

Figure 12:

5 CYK-4 and ZEN-4 associate in vivo and in vitro

Figure 13:

The N- terminus of CYK-4 is necessary and sufficient to bind to ZEN-4

Figure 14:

10 The central region of ZEN-4 is necessary and sufficient to bind to CYK-4

Figure 15:

A complex of CYK-4 and ZEN-4 is required for function in vivo

Figure 16:

Self-association of CYK-4 and ZEN-4

Figure 17:

A complex of MKLP-1 and HsCYK-4 in HeLa cells

5 Figure 18:

Centralspindlin and its role in the formation of
central spindle

In the Examples 1 - 5, if not otherwise stated, the
10 following materials and methods were used:

a) Strains and alleles

The *cyk-4(t1689ts)* allele was identified in a search
for maternal effect lethal mutations on chromosome III
15 (see (Gönczy et al., 1999b) for details). The strains
DR104, BW1535, BW1369, and RW7000 were obtained from
the CGC (C.elegans Genetics Center). The strain EU699
containing the *zen-4(or153ts)* allele was described by
Severson, et al., 2000. The end points of the
20 deficiency tDf10 (Heinke Schnabel, unpublished data)
are not molecularly defined, but it uncovers *cyk-4*,
lit-1, and *bli-5* and it does not uncover *unc-64*.

b) Antisera

Cyk-4 specific antisera were produced in rabbits using a His6-Cyk-4 fusion protein as immunogen (containing amino acids 407-613 of *cyk-4*). A GST-Cyk-4 fusion
5 containing amino acids 407-681 of Cyk-4 was coupled to a Hi-Trap NHS resin (Amersham-Pharmacia) and used to affinity purify anti-Cyk-4 antibodies which were used at a final concentration of 1:300. The antibodies used for the studies are specific for Cyk-4 since the
10 staining can be blocked with antigen, a similar pattern is observed when anti-GFP antibodies are used to detect a Cyk-4:GFP fusion construct, and the staining pattern is disrupted in *cyk-4* mutant embryos. The rat monoclonal YOL 1/34 anti-tubulin antibody was used at a
15 dilution of 1:200-500. Anti-GFP antibodies (Roche) were used at a dilution of 1:500. Antisera specific for Zen-4/MKlp1 was generously provided by Bill Saxton and Susan Strome (Univ. of Indiana) and used at a dilution of 1:4000. Antisera specific for Air-2 was
20 generously provided by Andy Golden (NIH) and used at a dilution of 1:1000.

c) Genetic mapping of Cyk-4

The *cyk-4* locus maps under the deficiency *tDf6* which
25 deletes a large fraction of the distal right arm of LGIII. Recombination mapping using *unc-32(e189)* *cyk-4(t1689ts)/dpy-18(e364)* *unc-25(e156)* placed *cyk-4* distal to (or very close to) *unc-25* (23/23 Dpy non Unc's carried the *cyk-4* mutation). Recombination
30 between *dpy-18 cyk-4/RW7000* which carries several Tc1

elements including one on the cosmid F14F7 gave rise to 45 Dpy non-Ts animals, 3 of which lacked the TC1 insertion on F14F7, indicating that the *cyk-4* gene is distal to this cosmid. Crosses to strains carrying the deficiencies *ctDf3*, *ctDf2*, *tDf10* revealed that *cyk-4(t1689ts)* is not uncovered by *ctDf3* and is uncovered by both *ctDf2* and *tDf10*. Since *tDf10* does not uncover *unc-64*, *cyk-4(t1689ts)* must be distal to *unc-64*.

10

d) Time Lapse recordings

Time lapse Nomarski imaging was performed as described previously (Jantsch-Plunger and Glotzer, 1999). Time lapse imaging of *Cyk-4:GFP* was performed on a Zeiss Axiovert microscope using a 100X/1.3 neofluar objective. The illumination source, an Atto-arc HBO-103, was reduced to 50% intensity. An intensified cooled CCD camera (GenIV pentamax, Princeton Instruments) was used for image acquisition. The camera and other electronics were controlled with MetaMorph software (Universal Imaging). Typical acquisition times were 40-80 msec. Each 10 seconds, 4-5 fluorescent images were acquired at different focal planes and a nomarski image was acquired. The fluorescent images were projected onto a single frame using the maximum intensity from the stack of images. Under these conditions, embryos could be filmed for more than one hour without affecting the cell cycle timing or pattern of cell divisions.

30

e) Rescue Experiments

To identify the *cyk-4* gene in this region cosmid DNA (from stocks kindly provided by Alan Coulson, Sanger Center) was coinjected with the *rol-6(su1006)* dominant marker (Mello et al., 1991) into the gonad of *unc-32* *cyk-4/qC1* worms. Heterozygous F1 hermaphrodites that carried the *rol-6* dominant marker were cloned to individual plates at 25°C and the presence of Unc progeny, indicating zygotic rescue of the *cyk-4* mutation, was assessed. Individual *unc-32*, *cyk-4* worms carrying the extrachromosomal arrays were cloned to individual plates to assess the extent of germline rescue. The *cyk-4* genomic rescue construct MP17, contains a 4.9 kb genomic *Xba*I fragment excised from K08E3 and inserted into pBS-KS+.

f) RNA interference

Approximately 500 bp of DNA corresponding to predicted coding regions of Rho (Y51H4A.B), Rac-1 (C09G12.8B), Cdc42 (R07G3.1), F22E12.2, Y32F6B.3, K08D3.9, K08E3.2, K08E3.3, K08E3.4, K08E3.6, K08E3.7, K08E3.8 were amplified by PCR and cloned into pGEM-T (Promega). Double stranded RNA was transcribed (Ambion) and annealed, and injected into the gonads of wildtype N2 hermaphrodites as described (Fire et al., 1998).

g) Production of Cyk-4:GFP transgenes

The GFP cassette from vector pPD119.16 was excised with BspLUIII and inserted into the unique NcoI site of MP17 (see above). This construct was linearized with XbaI, and complex arrays containing linearized genomic DNA and linearized rol-6(su1006) DNA were mixed in a ratio of 1:100:1 and injected into *unc-32(e189)* *cyk-4(t1689ts)/qC1* hermaphrodites. Rolling F1 heterozygotes were singled out at 25°C and rolling Unc F2 animals were picked. A line MG110, was obtained that gave stable rescue of the *cyk-4(t1689ts)* mutation.

The structure of the *cyk-4* gene was established by analysis of a large number of EST sequences available in the sequence databases at the Sanger Center and the National Institute of Genetics and by sequencing the clones yk63D6 and yk104g12 (kindly provided by Yuji Kohara). The structure of the gene is identical to the structure predicted by the *C. elegans* genome consortium.

20

h) Immunolocalization

Immunolocalization studies were performed as previously described (Jantsch-Plunger and Glotzer, 1999). Briefly, gravid hermaphrodites were placed on aminopropyl-silane treated slides, a coverslip was added, and sufficient pressure to extrude the embryos was applied. The slide was placed into liquid nitrogen. The coverslip was removed while the sample was still frozen, the preparation fixed with -20°C

methanol and then antibody staining was performed according to standard procedures.

i) Biochemical analysis of Cyk-4

- 5 The coding regions of Rho, Rac, and Cdc42 were PCR amplified and cloned into pET28b with an C-terminal polyhistidine tag. The GTPases were expressed at 25°C and purified using Ni²⁺-NTA-agarose (QIAGEN). Proteins were dialyzed into 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM
- 10 MgCl₂ and quick frozen. The GAP domain of Cyk-4 (amino acids 407-681) was cloned into pGEX4T-1. Proteins were expressed at 25°C and purified using GSH-agarose (Sigma). Proteins were dialyzed into 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl₂, 1 mM DTT and quick frozen.
- 15 To assess GAP activity, 15 pmol of the GTPases were loaded with 1 pmol ³²P-α-GTP in 20 mM Tris pH 7.6, 4 mM EDTA, 25 mM NaCl, 1 mM DTT, 1 mM ATP, 0.1 mg/ml BSA at room temperature. The sample was place on ice and MgCl₂ was added to 17 mM. GST-Cyk-4-GAP was added at the
- 20 indicated concentrations and, at intervals, samples were taken by dilution into 2% SDS, 20 mM EDTA. Aliquots were spotted onto TLC plates (PEI-cellulose, Machery-Nagel) and developed in 1M LiCl. The plates were dried and exposed using a Storm Phosphoimager,
- 25 (Molecular Dynamics) and the data analysis was performed using the public domain NIH Image program (developed at the U.S. National Institutes of Health; <http://rsb.info.nih.gov/nih-image/>).

Example 1

cyk-4 mutants initiate, but do not complete, cytokinesis

The *cyk-4(t1689ts)* allele was isolated in a screen for maternal effect embryonic lethal mutations on chromosome III (Gönczy et al., 1999b). The *cyk-4* locus is defined by a single, temperature sensitive (ts), allele. The phenotype of embryos derived from homozygous *cyk-4* hermaphrodites at the restrictive temperature (hereafter referred to as *cyk-4* mutant embryos) during the first division is shown in figure 1B. *cyk-4* mutant embryos appear normal until cytokinesis, except that defects in polar body extrusion are frequently observed (data not shown).

The first cleavage furrow forms at the correct time and place, it ingresses extensively, but, invariably, it regresses. Quantitation of the extent of furrow ingression in *cyk-4* mutant embryos reveals that, on average, furrows ingress to 73+/-13% (n=14) of the egg diameter. A multipolar spindle develops in the second cell cycle and the process of furrow ingression and regression occurs again. This pattern is repeated until the embryos become grossly disorganized. (Figure 1 shows that *cyk-4(t1689ts)* mutant embryos fail, to complete cytokinesis. Wildtype embryos (A) and embryos from *cyk-4* mutant hermaphrodites (B) were dissected from young adults, mounted on agarose pads and observed by time-lapse nomarski microscopy. The ingressing cleavage furrow is indicated (arrows). 10 μ m scale bars.)

Although the majority of cell divisions in worm development occur early in embryogenesis, cells of the germline and many cells in the nervous system are produced during post embryonic development (Sulston and
5 Horvitz, 1977). A number of mutations in genes required for cell division cause worms to become sterile and uncoordinated (O'Connell et al., 1998; Woollard and Hodgkin, 1999). To determine if *cyk-4* is required post embryonically, temperature shift experiments with worms
10 homozygous for the *cyk-4(t1689ts)* allele were performed (table 1). Homozygous animals grown at 16°C are viable and fertile. Homozygous *cyk-4* animals shifted to 25°C at the L4 stage produce embryos with the cytokinesis defects described above. Homozygous animals shifted to
15 25°C at earlier stages either fail to hatch or become sterile and uncoordinated, depending on the time of the temperature shift. Thus *cyk-4* is required postembryonically, perhaps due to its role in cell division. Unexpectedly, animals shifted at the L2/L3
20 stages become highly uncoordinated adults, even though most motor neurons would be expected to have completed all their divisions at the time of the shift. This may suggest that CYK-4 has additional roles besides its role in cell division. However, not out the
25 possibility cannot be ruled out that some of the cells in the ventral nerve cord divide later in *cyk-4* mutants.

To investigate why *cyk-4* mutant embryos fail to complete cytokinesis, actin and tubulin were localized
30 in wild-type and *cyk-4* mutant embryos. Both wild-type and mutant embryos contained deeply ingressing cleavage furrows that stain with an anti-actin antibody; the

results are shown in figure 2. Figure 2A,B shows that *cyk-4* mutant embryos produce deeply ingressing cleavage furrows, but do not form a prominent central spindle. Wild type (A, C) and *cyk-4* mutant embryos (B,D) were
5 fixed and stained for actin (green) and DNA (blue) (A,B); tubulin (green) and DNA (blue) (C,D). 10 μ m scale bars.

The metaphase spindles of *cyk-4* mutant embryos appeared normal. However, spindle morphology during early
10 anaphase was significantly different in mutant embryos as compared to wild type. In wild-type embryos (20/20) prominent microtubule bundles form between the separating masses of chromatin, forming the central spindle (figure 2C). In *cyk-4* mutant embryos (9/10)
15 such bundles were largely reduced and disorganized (figure 2D). It is concluded that CYK-4 is required for the organization of the central spindle during anaphase. Since the central spindle is required for cytokinesis, it is possible that the *cyk-4* mutant
20 embryos fail to complete cytokinesis because they fail to assemble the central spindle.

Example 2

Cloning of the *cyk-4* gene

25 To investigate the molecular basis for the phenotypes described above, it was first sought to map the *cyk-4* locus and clone the affected gene (see methods for details). The *cyk-4* gene maps distal to *unc-64* on the extreme right arm of LG III. Figure 3 shows the

positional cloning of the *cyk-4* locus. (A) A schematic of LGIII showing the positions of various loci and the extent of the deficiencies. *cyk-4* is uncovered by tDf10, tDf6, and ctDf2, but not ctDf3. (B) An enlargement of the physical map from the *unc-64* locus until the end of LGIII. The ability of various cosmid pools to rescue *cyk-4* is indicated. (C) A map of the predicted genes on K08E3. All the predicted genes except for K08E3.1 and K08E3.5 were inactivated by RNAi and only RNAi of K08E3.6 produced multinucleate embryos. (D) A schematic representation of the domain structure of CYK-4 and its human ortholog. The position of the point mutation identified in *cyk-4(t1689ts)* is indicated.

15 The *cyk-4* gene was then identified by functional rescue of the zygotic requirement for *cyk-4* using pools of cosmids. A pool of three cosmids (ZK520, W06F12, and K08E3) allowed *cyk-4* homozygotes to hatch and develop to adulthood at 25°C. These cosmids were injected individually and cosmid K08E3 contained rescuing activity. Further subcloning revealed that a 4.9 kb genomic fragment, predicted to contain the complete K08E3.6 gene and no other intact gene, could rescue the *cyk-4* zygotic and germline phenotypes. Finally, the coding region was amplified from DNA derived from *cyk-4(t1689)* homozygotes and sequenced and a single point mutation was identified that differed from the sequence provided by the genome project; this mutation was not observed in another line derived from the same parental strain. These data show that the defect in *cyk-4(t1689ts)* embryos is due to a point mutation in the K08E3.6 gene.

The predicted protein product of the *cyk-4* gene has a C-terminal domain that contains the consensus motifs of GTPase activating proteins for Rho family GTPases (figure 3). Adjacent to the C-terminal GAP domain is a
5 C1 domain that is predicted to bind to diacylglycerol or phorbol esters. At the amino terminus of the protein is a 90 amino acid region predicted to form a coiled-coil domain. The S15L point mutation found in *cyk-4(t1689ts)* , is located just amino terminal to the
10 coiled-coil domain. Human and mouse proteins with structural similarities to *cyk-4* have been described (Toure et al., 1998; Woollorton et al., 1999). These genes are expressed in a variety of proliferating tissues. In addition, the *Drosophila* sequence database
15 contains an entry (ascension no. AC005977 (CLOT 94)) that, together with CYK-4 and the previously mentioned human gene, share a common structure consisting of approximately 650 amino acids, an NH₂-terminal coiled-coil domain and a conserved C-terminus containing C1
20 and GAP domains. The structural conservation of CYK-4 suggests that its function is conserved among metazoans.

In the present invention, the the human and mouse cDNA's were identified by searching the DNA databases
25 with the *C.elegans* CYK-4 protein sequence.

Since the *cyk-4(t1689ts)* mutation may contain residual activity RNA-mediated interference (RNAi) was used to deplete embryos of CYK-4 protein.

Figure 4 shows that *cyk-4(RNAi)* causes disorganization
30 of the proximal gonad and affects formation of the

central spindle. Young adults were injected with *cyk-4* dsRNA and the injected animals were analyzed 30 hours after injection (B). The gonad of an uninjected worm is shown for comparison (A). Wild-type embryos (C) and
5 embryos from *cyk-4(RNAi)* injected animals (D) were fixed and stained for tubulin. 10 μ m scale bars.

RNAi of the predicted open reading frame K08E3.6 generated multinucleate embryos which exhibited a similar phenotype to that of the *cyk-4* mutant,
10 including loss of the central spindle (figure 4 D) and incomplete cytokinesis (not shown). Interestingly, the gonads of *cyk-4(RNAi)* animals become disorganized 30 hours post-injection (figure 4 B) and irregularly sized embryos are produced, suggesting that CYK-4 acts
15 not only during embryonic and zygotic development, but also in the female germline.

Example 3

Biochemical activity of the Cyk-4 GAP domain

20 The presence of a Rho-family GAP domain suggests that CYK-4 may regulate one or more GTPases of Rho branch of the GTPase superfamily. To determine whether CYK-4 is active as a GAP and whether its GAP activity is restricted to particular members of the Rho subfamily,
25 a recombinant fusion protein containing GST and the CYK-4 GAP domain was prepared and GTP hydrolysis assays were performed with recombinant *C. elegans* Rho, Rac, and Cdc42. The GAP domain of CYK-4 promotes GTP hydrolysis by all three tested GTPases. Figure 5 shows

that CYK-4 enhances GTP hydrolysis by Rho, Rac, and Cdc42. The GTPases were preloaded with ^{32}P - α -GTP and then GST-CYK-4-GAP or GST was added at the indicated concentration. Samples were taken at two minute
5 intervals, the labeled nucleotide was resolved by thin layer chromatography, the fraction of GTP and GDP was quantitated. This graph shows the fraction of GTP hydrolyzed at the 2 minute time point as a function of CYK-4 concentration. These data are representative of
10 at least three independent experiments.

However kinetic differences were observed. At the conditions used in the assays it was found that the CYK-4 GAP domain is more active towards Rac and Cdc42 than towards Rho. The human ortholog has a similar
15 activity profile *in vitro* (Toure et al., 1998). However, since CYK-4 has activity towards all three GTPases, these data are not sufficient to determine the *in vivo* target(s) of the CYK-4 GAP domain.

Next RNAi was used to determine which, if any, of the
20 Rho family GTPases are required for cytokinesis in the *C. elegans* embryo. RNAi experiments were performed with RhoA, Rac1, Cdc42 and three additional GTPases found in the genome that fall into the Rho subfamily. Approximately 90% of *Rho(RNAi)* embryos exhibit
25 cytokinesis defects in the first and/or second cell cycle (table 2 and figure 6).

Figure 6 shows that *rho(RNAi)* causes cytokinesis defects and *cdc42(RNAi)* causes defects in spindle positioning. Young adults were injected with the
30 indicated dsRNAs (see table 2) and the embryos produced

by the injected worms were analyzed by time lapse nomarski microscopy. Images from a wild-type (A), *rho(RNAi)* (B) and a *cdc42(RNAi)* (C) embryo are shown. 10 μ m scale bars.

- 5 In most embryos, furrow ingression was inhibited. Interestingly, central spindles assemble in *RhoA(RNAi)* embryos (data not shown). In contrast, 88% of *Cdc42(RNAi)* embryos complete cytokinesis normally. However, a distinct defect in the early embryo is
10 observed in 54% of *Cdc42(RNAi)* embryos; defects in spindle positioning are observed in P0 and/or P1. A minority (12%) of *Cdc42(RNAi)* embryos fail to initiate cytokinesis; in most cases, these embryos appear
15 osmotically swollen even when provided with osmotic support. *Rac(RNAi)* embryos hatch with high efficiency and did not exhibit a detectable phenotype in the early embryo. RNA interference experiments with the additional GTPases either alone or in combinations did not reveal any additional defects in the early embryo.
20 Thus *RhoA* is the only member of the Rho family that is clearly required for cytokinesis and is therefore likely to be the critical target for the CYK-4 GAP domain.

25 Example 4

The subcellular localization of Cyk-4

Next the subcellular localization of CYK-4 protein was determined. CYK-4 localization is cell cycle dependent

Figure 7 shows that CYK-4 localizes to the central spindle and division remnants. (A-F) Wild-type embryos were fixed and stained for CYK-4 (green), tubulin (red) and DNA (blue). The localization of CYK-4 to the
5 central spindle (arrow) in a one cell embryo (D) and a two cell embryo (F) is shown. The localization of CYK-4 to the division remnant from the polar body (A), and between the AB and P1 blastomeres is indicated with arrows. (E). (G) An embryo from a line expressing
10 CYK-4:GFP is stained with anti-GFP antibodies. The same structures are seen as with CYK-4 antibodies (arrow). (H) The intrinsic fluorescence of the gonad of a worm expressing CYK-4:GFP. CYK-4 is seen at the incomplete membranes of the syncytial gonad (arrow) and
15 in oocyte nuclei. 10 μ m scale bars.

In interphase cells, CYK-4 is present in the cytoplasm and slightly concentrated in the nucleus. CYK-4 is also highly concentrated in a spot at the anterior of the embryo, DNA labeling reveals that this localization
20 corresponds to the site of polar body extrusion. As embryos enter mitosis, CYK-4 protein concentrates around the mitotic spindle. In early anaphase, CYK-4 concentrates to the central spindle. As the cleavage furrow ingresses, CYK-4 becomes highly concentrated on
25 the central spindle into a structure that often appears ring shaped (not shown). Upon completion of cytokinesis, CYK-4 staining persists at division remnants. CYK-4 organized in ring-like structures averaging 1.2 μ m in diameter are occasionally observed
30 in the cytoplasm (not shown).

To determine if CYK-4 localizes to the central spindle prior to the onset of cleavage furrow ingression, the dynamics of CYK-4 localization in live embryos was investigated. To accomplish this goal a transgenic
5 line expressing a CYK-4:GFP fusion was generated and its localization followed by time lapse microscopy. The CYK-4:GFP fusion is partially functional since *cyk-4 xEx1[cyk-4:GFP]* animals are viable and fertile at 25°C whereas the parental *cyk-4* strain is inviable
10 at 25°C. However, the fusion construct does not fully rescue the mutation, since about 40% of embryos produced by this line fail to hatch (table 1).

Low light level fluorescence microscopy was used to visualize CYK-4:GFP in living embryos. Embryos were
15 imaged using a multi-mode imaging system whereby a series of z-sections and a nomarski image were recorded every 10 seconds. The fluorescent images from each time point were projected to form a single image.

Figure 8 shows the time lapse analysis of CYK-4:GFP.
20 An embryo from a line expressing CYK-4:GFP was imaged using low light level microscopy. The central spindle localization of CYK-4 is observed prior to furrow ingression. 10 µm scale bars.

These recordings reveal that CYK-4 accumulates on the
25 central spindle prior to the initiation of furrowing (figure 8; 3:40). The CYK-4 that localizes to the central spindle becomes compressed into a bright spot which persists at the division remnant. The remnant persists for several cell cycles although instances
30 were observed whereby the remnant (sometimes from the

polar body) detaches from the cortex and is observed as a discrete spot in the cytoplasm. This detachment of CYK-4 from division remnants likely accounts for the CYK-4 rings seen in fixed specimens. It is concluded
5 that CYK-4 localization on the central spindle precedes furrow ingression.

Example 5

Cyk-4 and zen-4/CeMklp1 are functionally interdependent

- 10 There are remarkable similarities between CYK-4 and the kinesin-like protein ZEN-4/CeMKLP1 (Powers et al., 1998; Raich et al., 1998). zen-4 mutant embryos also initiate, but fail to complete cytokinesis. They also fail to assemble a robust central spindle in early
15 anaphase. Furthermore, ZEN-4 localizes to the central spindle and persists at division remnants after completion of cytokinesis. To test whether these proteins functionally interact, it was first assessed whether CYK-4 and ZEN-4/CeMKLP1 co-localize.
- 20 Embryos expressing CYK-4:GFP were fixed and CYK-4 and ZEN-4 were localized simultaneously (using an anti-GFP antibody to detect CYK-4:GFP). The two proteins co-localize both on central spindle structures and on division remnants (Figure 9A-C). It was next
25 investigated if ZEN-4 localization requires functional CYK-4 protein. ZEN-4 staining of *cyk-4* mutant embryos reveals that ZEN-4 localization to the central spindle is absent (figure 9E), although staining of some microtubule bundles in the spindle midzone could be

detected using an AIR-2 antibody (figure 9G). Thus, recruitment of ZEN-4 to the central spindle is CYK-4 dependent.

Figure 9 shows an embryo expressing CYK-4:GFP stained for GFP (A), ZEN-4/CeMKLP1 (B) and the merged image (C). CYK-4 and ZEN-4/CeMKLP1 colocalize at division remnants (arrow) and a central spindle (arrowheads) structures. ZEN-4 localization to the central spindle is CYK-4 dependent (arrow). Wild-type (D) and *cyk-4(t1689ts)* embryos (E) were fixed and stained for ZEN-4/CeMKLP1 (green), tubulin (red) and DNA (blue). AIR-2 localization to the central spindle is CYK-4 independent (arrow). Wild-type (F) and *cyk-4(t1689ts)* embryos (G) were fixed and stained for AIR-2 (green), tubulin (red) and DNA (blue). CYK-4 maintenance to division remnants (arrowheads) is ZEN-4/CeMKLP1 dependent. *zen-4(or153ts)* worms were maintained at 16°C and either fixed immediately (H) or shifted to 25°C for 18 minutes (I). Embryos were fixed and stained for CYK-4 (green), tubulin (red) and DNA (blue). 10 µm scale bars.

Next it was tested whether maintenance of ZEN-4 at division remnants requires functional CYK-4. *cyk-4* mutant embryos grown at 16°C were shifted to 25°C for 15 minutes prior to fixation and staining with anti-ZEN-4 antibodies. The number of cells and number of division remnants labeled with the anti-ZEN-4 antibody were counted. Embryos maintained at the permissive temperature had a large number of ZEN-4 staining division remnants (table 3) whereas the embryos shifted to the non-permissive temperature lacked defined

staining of division remnants. Thus both recruitment of ZEN-4 to the central spindle and its maintenance at division remnants is CYK-4 dependent. The reverse experiment was conducted with a temperature sensitive allele of *zen-4(or153ts)*. In this case CYK-4 staining at division remnants was observed in *zen-4* mutant embryos at the permissive temperature but this staining disappeared upon a brief shift to the non-permissive temperature (figure 9H,I and table 3). Thus maintenance of CYK-4 at division remnants is ZEN-4 dependent. It is concluded that CYK-4 and ZEN-4/CeMKLP1 colocalize and that the two proteins are interdependent for their localization.

Next, it was determined if embryos carrying mutations in both *cyk-4* and *zen-4* are distinguishable from the single mutants. Two strains were built, one strain was homozygous for *zen-4(or153ts)* and heterozygous for *cyk-4(t1689ts)* and the second strain was homozygous for *cyk-4(t1689ts)* and heterozygous for *zen-4(or153ts)*. Both strains were viable at 16°C, but they failed to produce doubly homozygous larvae. It was found that worms of genotype *unc-32(e189) cyk-4(t1689ts) /qC1 III, zen-4(or153ts)* laid a fraction of embryos that arrested during embryonic development, typically before the comma stage. Thus *cyk-4(t1689ts)* and *zen 4(or153ts)* are synthetically lethal.

In the subsequent Examples, the following Materials and Methods were used:

i) Worm Strains and Alleles

The following alleles were used: N2(Bristol), CB4856, *cyk-4(t1689ts)*, *unc-64*, *bli-6(sc16)*, *unc-24(e138)*,
5 *unc-44(e1260)*, *lag-1(q385)*, and *mIs11 IV*. Some strains were obtained from the *C. elegans* Genetics Center.

ii) Isolation and mapping of *cyk-4* suppressor alleles

Suppressors of the *cyk-4(t1689ts)* mutation were obtained by mutagenizing *cyk-4(t1689ts)* animals with
10 30-40 mM EMS or 0.5 mM ENU. P0 animals were allowed to self fertilize for two generations at the permissive temperature. When F2 animals reached early adulthood, the population was shifted 20°C and fertile animals were selected. Approximately 110,000 F1 genomes were
15 screened and 18 suppressor mutations, all but 2 being unambiguously independent, were isolated. While all of the suppressor strains were viable and fertile at 20°C, none were able to grow at 25°C, suggesting that none of them precisely reverted the original mutation. Several
20 intragenic suppressor mutations were identified. The ZEN-4 coding region of the remaining mutants were sequenced and 7 strains were found to contain substitutions within the CYK-4 binding region of ZEN-4 and one contained a substitution in the catalytic
25 domain. One suppressor strain, *xs82*, was characterized in detail. Suppressor activity was mapped using single nucleotide polymorphisms (SNPs) to the central region of chromosome IV (see methods). The ZEN-4 coding region was sequenced in this strain and a point mutation was

found that causes a substitution of glutamic acid for a lysine at position 502 (fig 15A).

iii) Cell Culture

HeLa cells were routinely grown in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin.

iv) Antibodies

Rabbit CYK-4 specific and ZEN-4 specific antisera were reported previously (Jantsch-Plunger et al., 2000).

CYK-4 and ZEN-4 antibodies were affinity-purified with His6-CYK-4 (407-613) or His6-ZEN-4 (578-775) immobilized on NHS-Sepharose (Pharmacia).

MKLP-1 specific antisera and HsCYK-4 specific antisera were produced in rabbits and mice (Gramsch Laboratories, Schwabhausen, Germany) using C-terminal peptides (QLGPGYQHHAQPKRKPP and SKSKSATNLGRQGNFFASPMLK, respectively) conjugated to keyhole limpet hemocyanin as immunogens. Rabbit antibodies were affinity purified using peptides immobilized on Poros epoxide resin.

v) Plasmids

A cDNA clone for ZEN-4 in pBluescript (yk391b3) which lacks 13 nts at 5' of the coding region which were introduced by PCR. The pCBD-TEV vector was constructed by inserting the sequences encoding the chitin-binding domain (CBD) and a TEV protease site into pET28a

(Novagen). ZEN-4 fragments were amplified by PCR and cloned into pCBD-TEV.

vi) In Vitro Binding Assay

Full length and fragments of CYK-4 and ZEN-4 were
5 expressed by in vitro transcription and translation
system with reticulocyte lysates using the TNT® Coupled
Reticulocyte Lysate Systems (Promega) or the
PROTEINscript™ II (Ambion) kits, typically in 20 µl
reactions. Full length proteins without tag were
10 expressed from the T3 promoter of pBluescript SK(-).
Fragments of CYK-4 and ZEN-4 tagged with chitin-binding
domain (CBD) at N-terminus were expressed from the T7
promoter of pET-CBD. In some experiments (Fig. 12C,
13C and 16), CYK-4 and ZEN-4 were co-expressed in the
15 same reactions. In other experiments, they were
separately expressed and mixed. Following incubation
at 20°C for 30 min in 100 µl buffer A (20 mM Hepes,
150 mM NaCl, 2 mM MgCl₂, 10 mM EDTA, 1 mM DTT, 1 mM
PMSF, 10 µg/ml leupeptin, 10 µg/ml pepstatin, 10 µg/ml
20 chymostatin) with 0.5% (w/v) Triton X-100, ZEN-4 or
CYK-4 proteins were immunoprecipitated with specific
antibodies, or affinity-purified by chitin beads. For
immunoprecipitation, 0.5 µg antibody was added to the
reactions and incubated on ice for 1 hr, followed by
25 incubation with 5 µl protein A-Sepharose beads at 4°C
for 1h. For CBD-affinity purification, 5 µl of chitin
beads (New England Biolabs) were added. In both cases,
the beads were washed three times with buffer A
containing 0.5% (w/v) Triton X-100. Proteins bound to
30 the beads were analyzed by SDS-PAGE followed by
autoradiography with PhosphoImager.

vii) Preparation of Cell Lysates

C. elegans embryos were prepared by bleaching a synchronous culture of adult worms grown on "egg plates" as described (Lewis and Fleming, 1995). The embryos were washed with buffer A without Triton-X 100 and frozen with liquid nitrogen and kept at -80°C until use. Embryos were crushed by grinding in a mortar and pestle in liquid nitrogen.

HeLa cells were synchronised by treatment with 0.1 µg/ml nocodazole for 16 h. Cells were washed twice with cold PBS, frozen by liquid nitrogen and kept -80°C until use. Cells were lysed and thawed by suspending into 10 volumes of buffer A with 0.5% (w/v) Triton X-100.

viii) Preparation of Microtubule-binding Fraction

Frozen pellet (0.5 ml) of nocodazole arrested M-phase cells was thawed and lysed in 5 ml ice-cold BRB80 (80 mM K-Pipes, 1 mM MgCl₂, 1 mM EGTA, pH 6.8) with 0.1% (w/v) Triton X-100. The lysate was clarified by centrifuging at 10,000 x g for 15 min. The resulting supernatant was centrifuged at 25,000 x g for 20 min at 4°C in S100AT6 rotor (Hitachi). Microtubules polymerized with glycerol and taxol was added to the supernatant. After incubating at 20°C for 20 min, microtubules were pelleted by centrifuging at 25,000 x g for 20 min at 20°C. The bound proteins were released from microtubules by incubation in 0.5 M NaCl, 5 mM ATP in BRB80 at 20°C for 20 min, followed by centrifugation at 25,000 x g for 20 min at 20°C.

ix) Mass Spectrometry analysis

Hydrodynamics

Sedimentation coefficient was estimated by ultracentrifugation through 2 ml linear gradient of 5 to 20% (w/v) sucrose in buffer A without Triton X-100 using S55S rotor (Hitachi). 150 µl cell lysate or microtubule binding fraction was applied. Chicken ovalbumin (3.4 S), bovine gamma globulin (7.1 S), bovine catalase (11 S) and bovine thyroglobulin (19 S) were used as standards. The diffusion coefficient was estimated by gel filtration using Superdex 200 column (30 ml) in FPLC system (Pharmacia).

Immunoprecipitation and Western Blotting

Lysates (500 µl) were precleared with 50 µl protein A-Sepharose beads. For immunoprecipitation from worm embryos, 1 µg affinity-purified antibody was added to the lysate. After incubation on ice for 1 hr, immunocomplex was recovered by incubation with 5 µl protein A-Sepharase (Pharmacia) at 4°C for 1 hr. For immunoprecipitation from HeLa cells, antibodies were covalently immobilized on protein A-beads (1 µg per 1 µl beads) with dimethyl pimelimidate. The precleared lysate was incubated antibody-beads at 4°C for 1 to 4 h. The beads were washed briefly with buffer A plus 0.5 % Triton X-100 three times.

For western blotting, samples were run on 7.5% SDS-PAGE gel and electrotransferred to a nitrocellulose membrane (HiBond ECL, Amersham).

x) Immunolocalization

Immunolocalization studies in worm embryos were performed as previously described ref. In brief, gravid hermaphrodites were placed on aminopropyl-silane treated slides, a coverslip was added, and sufficient pressure to extrude the embryos was applied (Jantsch-Plunger et al., 2000). The slide was placed into liquid nitrogen. The coverslip was removed while the sample was still frozen, the preparation was fixed with -20°C methanol, and antibody staining was performed according to standard procedures. Immunolocalization studies using HeLa cells were performed according to standard procedures following fixation in -20 °C methanol.

15 Example 6

Central spindle assembly is independent of RhoA

The process of central spindle assembly is dependent on the RhoGAP protein CYK-4. In the previous Examples, it was found that RhoA is essential for cytokinesis while Rac and Cdc42 are not (Jantsch-Plunger et al., 2000). Since RhoA is required for cytokinesis, it was tested if this GTPases is also required for central spindle assembly. To inactivate RhoA worms were grown on bacteria expressing dsRNA from the coding region of the gene (Timmons and Fire, 1998). Embryos were fixed and immunofluorescence-stained for CYK-4, microtubules and DNA with anti-CYK-4 antibody, anti- α -tubulin antibody and Hoechst 33342). In both control embryos and

rhoA(RNAi) embryos, central spindles formed and were prominently labeled with anti-CYK-4 antibodies.

Although RhoA dsRNAi causes a fully penetrant inhibition of cytokinesis, central spindle assembly occurs normally, and CYK-4 localizes to the central spindle (figure 11). Thus the requirement for RhoA in cytokinesis can not be accounted for by a requirement for RhoA in central spindle assembly. These data indicate that the requirement for CYK-4 in central spindle assembly is independent of its ability to regulate RhoA.

Example 7

CYK-4 and ZEN-4 form a complex in vivo and in vitro

Since central spindle assembly and cytokinesis requires both CYK-4 and ZEN-4 and these two proteins are interdependent for their proper localization, it is possible that these factors exist in a stable biochemical complex. In order to test this possibility, immunoprecipitation experiments were performed using extracts prepared from early *C. elegans* embryos. When embryo extracts were immunoprecipitated using anti-CYK-4 antibodies, it was found that significant amount of ZEN-4 co-immunoprecipitated suggesting the existence, in vivo, of a stable complex containing CYK-4 and ZEN-4 (fig. 12A).

To determine whether CYK-4 and ZEN-4 are competent to interact in the absence of other nematode proteins, the two proteins were produced by in vitro translation and

subjected to immunoprecipitation. When CYK-4 and ZEN-4 (fused to the chitin binding domain (CBD)) were translated in vitro and subsequently mixed, both proteins could be recovered in high yield by chitin beads (fig. 12B). The co-precipitation of CYK-4 was dependent on ZEN-4; CYK-4 was not recovered on chitin beads when ZEN-4 was substituted by CBD alone. Moreover, when luciferase was substituted for CYK-4, it did not co-precipitate with ZEN-4. The association between CYK-4 and ZEN-4 could also be detected when anti-CYK-4 antibodies were used to retrieve the complex (fig. 12C).

Figure 12 shows that CYK-4 and ZEN-4 bind to each other in vivo (A) and in vitro (B and C). (A) CYK-4 and ZEN-4 were immunoprecipitated from worm embryo extracts with anti-CYK-4 antibody, anti-ZEN-4 antibody, or with non specific rabbit IgG as a control. The immunoprecipitates were resolved on SDS-PAGE gels followed by western blotting with an anti-ZEN-4 antibody. Mock immunoprecipitation without extract was included to control for cross reactivity with the antibodies. ZEN-4 specifically co-immunoprecipitated with CYK-4. (B) ³⁵S-labeled CYK-4 (or luciferase, LUC) and chitin-binding domain (CBD)-tagged ZEN-4 (or CBD alone) were separately expressed by in vitro translation (left panel). Translation reactions were mixed and incubated in the indicated combinations and CBD-ZEN-4 or CBD alone were recovered with chitin beads (right panel). In this and all gels in this paper the input lanes contain the same amount of translation product as was added to the beads used for precipitation. The precipitates were resolved on

SDS-PAGE gels and the labeled products detected using a phosphoimager. CYK-4 co-purified with CBD-ZEN-4 while the luciferase control did not. (C) CYK-4 (or luciferase) and CBD-ZEN-4 (or CBD alone) were
5 co-expressed as ³⁵S-labeled proteins in the indicated combinations (left panel). CYK-4 was immunoprecipitated with an anti-CYK-4 antibody (right panel). ZEN-4 co-immunoprecipitated with CYK-4.

10 Example 8

Delineation of the region of CYK-4 necessary to bind to ZEN-4

Since the binding between CYK-4 and ZEN-4 could be easily reconstituted using in vitro translated
15 proteins, this simple assay was used to dissect the regions of the two proteins that mediate this interaction. The experiment first concentrated on CYK-4. The N-terminal 30 amino acids of CYK-4 are poorly conserved and are followed by a 90 amino acid region
20 predicted to form a coiled-coil (see schematic fig. 13D). The C-terminal 250 amino acids contains a RhoGAP domain that is active in vitro against RhoA, Rac, and Cdc42 (Jantsch-Plunger et al., 2000). The RhoGAP domain is preceded by a C1 domain, a cysteine-rich domain that
25 mediates interactions with diacylglycerol (Hurley and Meyer, 2001) other ref. Truncations of the C-terminus of CYK-4 revealed that the ZEN-4 binding region is contained within the N-terminal 232 amino acids (fig. 13A). Further truncations within this region
30 indicated that residues 1-120 (from the N-terminus to

the end of the coiled-coil region) are sufficient to bind efficiently to ZEN-4 (fig. 13B). Deletion of the N-terminal 35 amino acids of CYK-4 prevented the interaction with ZEN-4. A near full length version of
5 CYK-4 lacking only the N-terminal 35 amino acids does not bind ZEN-4 (fig 13C). Thus the ability of CYK-4 to interact with ZEN-4 depends on the N-terminal 120 residues of CYK-4 (fig. 13D).

Figure 13 shows the results of the in vitro binding
10 assay that was used to define the ZEN-4 binding region of CYK-4.

(A) Full-length ZEN-4 and C-terminal deletion fragments of CYK-4 (1-232, 1-373 and 1-468) were separately expressed as ³⁵S-labeled proteins by in vitro
15 translation (left two panels). The reaction products were mixed and after incubation ZEN-4 was immunoprecipitated with an anti-ZEN-4 antibody (right panel). The three fragments of CYK-4 co-immunoprecipitated with ZEN-4. (B) Full length CYK-4
20 (1-681) and CYK-4 with N-terminal deletion (35-681) were expressed as ³⁵S-labeled proteins and mixed with unlabeled CBD-ZEN-4 (left panel). After incubation, CBD-ZEN-4 was affinity purified on chitin beads (right panel). CYK-4 (35-681) did not copurify with CBD-ZEN-4, but full length CYK-4 did. (C) CBD-CYK-4 fragments
25 (1-232, 35-232, 121-232, 1-120 and 35-120) and full length ZEN-4 (or luciferase as a control) were co-expressed as ³⁵S-labeled proteins by in vitro translation (left panel). CBD-CYK-4 fragments were
30 affinity purified (right panel). ZEN-4 copurified with CYK-4 (1-232) and (1-120), but not with CYK-4 (35-232),

(121-232) or (35-120). (D) A schematic summary of the CYK-4 derivatives tested. The ZEN-4 binding region was defined as residues 1-120 of CYK-4. This region contains a coiled coil region and a N-terminal
5 extension.

Example 9

Delineation of the ZEN-4 region required to bind CYK-4

Next, the in vitro assay was used to define the region
10 of ZEN-4 that binds to the N-terminal binding of CYK-4. Initially the CYK-4 binding activity of full length ZEN-4 was compared to that of three C-terminal deletion fragments of ZEN-4: the N-terminal catalytic core alone (1-434), the catalytic core domain and the linker
15 region (1-507), and a longer derivative that also includes the coiled coil domain (1-603). The full length protein bound CYK-4 with high affinity, as did the next longer fragment (1-603), but the two smaller fragments did not interact with CYK-4 (fig. 14A). Next
20 it was examined whether the binding activity could be further localized within the central region of ZEN-4. A minimal binding domain consisting of 169 amino acids was defined (fig. 14B). This region appears to consist of two elements, the linker region and the coiled coil;
25 neither of these individual elements had detectable binding activity on their own.

The interaction of CYK-4 with the neck linker/coiled coil region of ZEN-4 is particularly interesting in light of recent studies that indicate that in

conventional kinesin, the neck linker region is critical for transducing chemical energy into mechanical energy (Case et al., 2000; Rice et al., 1999) (see discussion).

- 5 Figure 14 shows the results of the in vitro binding assay that was used to show that the central region of ZEN-4 is necessary and sufficient to bind to CYK-4.

Full length ZEN-4 (1-775) and C-terminal deletion fragments of ZEN-4 (1-603, 1-507 and 1-434) were
10 ³⁵S-labeled by in vitro translation and incubated with unlabeled CYK-4 (or luciferase as a control) (left panel). CYK-4 was precipitated with anti-CYK-4 antibody (right panel). Full length ZEN-4 and ZEN-4 (1-603) co-precipitated with CYK-4, while shorter
15 fragments (1-507, 1-434) did not. (B) CBD-tagged fragments of ZEN-4 (1-603, 1-434, 435-603, 435-507 and 503-603) were expressed in an unlabeled form and incubated with ³⁵S-labeled CYK-4 (1-232) (left panel). ZEN-4 fragments were pulled down by affinity
20 chromatography using chitin beads (right panel). CYK-4 (1-232) copurified with ZEN-4 (1-603) and (435-603), but not with ZEN-4 (1-434), (435-507) or (503-603).
(C) A schematic summary of the ZEN-4 derivatives tested. ZEN-4 fragments containing residues (435-603)
25 associate with CYK-4, while the fragments lacking this region did not. This region contains a "neck" region C-terminal to the kinesin catalytic core and a coiled coil region.

Example 10

a) The product of *cyk-4(t1689ts)* does not interact with ZEN-4.

Although the amino terminal region of CYK-4 exhibits
5 poor sequence conservation at the primary sequence
level, earlier studies had indicated that this region
is crucial for function since the mutant allele that
was used to identify the *cyk-4* gene had a Ser to Leu
substitution at position 15. Since this point mutation
10 maps into the ZEN-4 binding determinant and since, in
vivo, this mutation seems to affect the ability of CYK-
4 and ZEN-4 to colocalize, it was tested whether this
mutation also affects the ability of these two proteins
to interact in vitro. The S15L mutation was introduced
15 into the amino terminal fragment of CYK-4 and used for
ZEN-4 binding assays. Whereas an interaction between
the N-terminal domain of CYK-4 and the central region
of ZEN-4 can be readily detected, the S15L mutant does
not interact with ZEN-4 (fig. 15B). This experiment
20 indicates that the primary cause for the defect in *cyk-4(t1689ts)* is a defect in the interaction with ZEN-4.

b) In vivo, ZEN-4 is in a stoichiometric complex with
Cyk-4

To gain further insight into the molecular architecture
25 of the CYK-4/ZEN-4 complex and to determine whether a
the majority of ZEN-4 is in a complex with CYK-4 in
vivo, sucrose density gradient centrifugation
experiments were performed with extracts prepared from
C. elegans embryos. When wild-type extracts are
30 prepared in the presence of 0.6 M NaCl, ZEN-4 migrates

as a symmetrical 9 S peak (fig. 15C). CYK-4 migrates at an identical S-value (data not shown). To determine whether the migration of ZEN-4 on sucrose gradients was dependent on its association with CYK-4, advantage was taken of the finding that the *cyk-4(t1689)* allele is specifically defective in its ability to bind to ZEN-4. When extracts were prepared from *cyk-4* mutant embryos and subjected to sucrose density centrifugation, ZEN-4 migrates as a symmetrical peak with a sedimentation value of 6 S, significantly less dense than ZEN-4 sediments in wild type extracts (fig. 15C). These data indicate that, in vivo, the majority of ZEN-4 is in a complex with CYK-4.

c) In vivo evidence for the CYK-4/ZEN-4 interaction domains

To gain further insight into the mechanism of CYK-4 function in vivo, it was sought to identify extragenic suppressors of the *cyk-4(t1689ts)* mutation. Homozygous *cyk-4(t1689ts)* animals were mutagenized and allowed to self fertilize for two generations at the permissive temperature. When the F2 animals reached early adulthood, the temperature was shifted to 20°C to impose a selection for fertile animals carrying presumptive suppressor mutations. By screening through approximately 100,000 F1 genomes, 18 suppressor mutations were identified (see methods). Intragenic suppressors were identified by sequencing of the *cyk-4* locus PCR amplified from suppressor strains. Six suppressor strains contain additional point mutations in the N-terminus of CYK-4; all of the mutations code

for amino acid substitutions within the biochemically defined ZEN-4 binding region.

- In addition to the mutations found within the *cyk-4* gene itself, extragenic suppressor mutations were also identified. One suppressor strain that does not contain any mutations in the *cyk-4* gene was characterized in more detail. The suppressor activity was mapped using single nucleotide polymorphisms (SNPs) to the central region of chromosome IV (see methods).
- 10 Since the *zen-4* gene maps to this region, the coding region of the *zen 4* gene was sequenced. This strain, *xs82*, was found to contain a point mutation that causes a substitution of glutamic acid for a lysine at position 502 (fig. 15A). Importantly, this substitution
- 15 maps directly to the region of ZEN-4 that was found to mediate the interaction with CYK-4 in vitro. To confirm that the substitution in *zen-4(xs82)* is responsible for the suppressing activity, the position of the suppressor was mapped to less than 1 cM
- 20 surrounding the *zen-4* locus. This mapping data combined with the fact that the sequence polymorphism maps to the CYK-4 binding region suggests strongly that these point mutations are responsible for the suppressing activity.
- 25 To determine whether the substitution, E502K, has any phenotype on its own, in the absence of the *cyk-4(t1689)* allele, *cyk-4(t1689)* was crossed out and worms homozygous for *zen-4(xs82)* were identified. These worms grew normally at 16°C, 20°C, and 25°C.

d) ZEN-4(xs82) partially restores binding to CYK-4 in vitro

As mentioned above, CYK-4 S15L is unable to interact with ZEN-4 in the in vitro binding assay. If the
5 immediate consequence of the S15L substitution in the N-terminus of CYK-4 is defective ZEN-4 binding, then an extragenic suppressor mutation in *zen-4* that rescues *cyk-4(t1689)* might be expected to restore binding to CYK-4 S15L. To test this possibility a N terminal
10 fragment of CYK-4 carrying the S15L point mutation was translated and this product was mixed with a C terminal fragment of ZEN-4 carrying either the wild-type glutamic acid at position 502 or the lysine substitute allele. The wild-type CYK-4 fragment bound equally well
15 to wild-type and the E502K derivative of ZEN-4. As discussed above the CYK-4 S15L is unable to bind to wild-type ZEN-4. However, CYK-4 S15L was able to bind to ZEN-4 E502K, though this interaction was weaker than that seen with the wild-type proteins (fig. 15A). These
20 data, together with the genetic suppression, prove that the interaction between the N-terminus of CYK-4 and the central region of ZEN-4 is crucial for its function in vivo.

Figure 15 shows that a complex of CYK-4 and ZEN-4 is
25 required for function in vivo

(A) A screen for suppressors of *cyk-4(t1689ts)* identified a point mutation of *zen-4(xs82)*. This allele has a G to A point mutation, resulting in substitution of glutamate at residue 502 to lysine.

30 (B) The E502K mutation partially restores binding to

CYK-4 S15L. CYK-4 fragments (1-232, 1-232 with a point mutation S15L, 35-232) were expressed as ³⁵S-labeled protein and incubated with unlabeled ZEN-4 fragments (435-775, 435-775 with the E502K mutation, 609-775).

5 ZEN-4 fragments were precipitated with anti-ZEN-4 antibody. CYK-4 (1-232) co-precipitated with ZEN-4 (435-775) but not with ZEN-4 (609-775) as shown in Figure 13. The S15L mutation in CYK-4 abolishes its ability to bind to ZEN-4 (CYK-4 1-232 S15L and ZEN-4

10 435-775 wt). However, the suppressor mutation in ZEN-4 (E502K) partially recovered this interaction ((CYK-4 1-232 S15L and ZEN-4 435-775 E502K). The ZEN-4 E502K mutation does not affect the binding to wild-type CYK-4. (C) The majority of ZEN-4 is in a complex with

15 CYK-4 in vivo. Extracts were made from wild type (N2) embryos or *cyk-4(t1689ts)* embryos. Sedimentation of ZEN-4 was analyzed by sucrose density gradient centrifugation followed by western blotting. The samples were spiked with the indicated standards and

20 they ran identically in the two gradients. ZEN-4 from wild type embryos sediments at 8 S, whereas ZEN-4 from *cyk-4* mutant embryos sediments at 7S.

Example 11

25 CYK-4 and ZEN-4 self-associate

Thus far it has been established that central spindle assembly is dependent on an interaction between CYK-4 and ZEN-4 and have defined the regions of both proteins that are required for this interaction. Interestingly,

30 both binding domains contain coiled coil regions; these

regions are required for binding activity. Since coiled coils are often dimerization motifs, and since kinesin motors are often composed of two motor domains tethered together through a coiled coil, it was
5 examined whether CYK-4 and ZEN-4 are individually able self-associate.

To assess if CYK-4 self associates, full length CYK-4 and the CYK-4 derivative 1-232 were co-expressed. As a control, the full length protein was substituted by a
10 truncated version lacking the N-terminal 120 amino acids. The longer CYK-4 fragments were immunoprecipitated with an antibody directed against the C-terminus of CYK-4 and the co-immunoprecipitation of the short N-terminal fragment was assessed. The
15 N-terminal fragment bound to full length CYK-4 but not to CYK-4 lacking the N-terminal domain (figure 16A). These data demonstrate that CYK-4 self associates. This association is likely mediated by the coiled-coil domain.

20 The capacity of ZEN-4 to self-associate was examined using a similar strategy. Full length ZEN-4 was co-expressed with affinity-tagged deletion derivatives of ZEN-4. Neither the N-terminal region (1-507) nor the C-terminal region (604-775) of ZEN-4 bound appreciably
25 to full length ZEN-4, but two internal fragments of ZEN-4 (503-775; 435-603) did bind to full length ZEN-4 (figure 16B). The region common to these two fragments consists of residues 503-603 which is the region predicted to form a coiled coil domain.

The ability of CYK-4 and ZEN-4 to self-associate in vitro raise the possibility that in vivo, the CYK-4/ZEN-4 complex may contain, at a minimum, two molecules each of CYK-4 and ZEN-4.

5 Figure 16 shows the self-association of both CYK-4 and ZEN-4

(A) CYK-4 (1-232), which does not contain the epitope recognized by the anti-CYK-4 antibody, was co-expressed as a ³⁵S-labeled protein with CYK-4 (1-681) or
10 (121-681), which do contain the epitope for this antibody (left panel). CYK-4 (1-681) and (121-681) were immunoprecipitated. CYK-4 (1-232) co-immunoprecipitated with CYK-4 (1-681), but not with CYK-4 (121-681). (B) CBD-tagged fragments of ZEN-4
15 (1-507, 503-775, 435-603 or 604-775) were co-expressed with untagged ZEN-4 (1-775) (left panel). CBD-tagged fragments were purified by affinity chromatography with chitin beads (right panel). Untagged ZEN-4 (1-775) copurified with CBD-ZEN-4 (503-775) and (435-603), but
20 not with ZEN-4 (1-507) or (604-775). The low extent of labelling of 604-775 as compared to 435-603 is attributable to low cysteine and methionine content of the C-terminal fragment.

25 Example 12

The human orthologs of CYK-4 and ZEN-4, HsCYK-4 and MKLP1, interact in vivo and colocalize.

In *C. elegans*, CYK-4 and ZEN-4 associate in vivo and in vitro and this complex is important for central spindle

assembly and cytokinesis. To extend these findings it was evaluated whether mammalian cells contain a stable complex containing the human orthologs of these proteins, HsCYK-4/MgcRacGAP (Hirose et al., 2001; Toure
5 et al., 1998; Woollorton et al., 1999) and MKLP1, respectively. Extracts were prepared from mitotic HeLa cells and antibodies directed against HsCYK-4 or MKLP1 were used for immunoprecipitation followed by western blotting. MKLP1 could be co-immunoprecipitated with
10 anti-HsCYK-4 antibodies and vice versa (fig. 17a). The immunoblots reveal that small amounts of HsCYK-4 and MKLP1 migrate with reduced mobility, likely due to phosphorylation.

To obtain evidence that these proteins play a similar
15 role in human cells as was shown previously for the nematode proteins, the localization of HsCYK-4 and MKLP1 was examined in cultured (HeLa) human cells. During all stages of the cell cycle the two proteins precisely co-localize (insets fig 17b). In early
20 anaphase, the two proteins localize to a discrete, central region of the central spindle. Three dimensional reconstruction of optically sectioned anaphase cells reveals that each bundle of microtubules in the central spindle is labeled at its distal end by
25 MKLP1 antibodies. During mid-to-late anaphase, the MKLP1 staining region is $0.93 \pm 0.25 \mu\text{m}$ in length (n=56). This region largely corresponds to the region that appears deficient in tubulin staining, but this is a known artifact caused by epitope masking (Saxton and
30 McIntosh, 1987). The extent of staining is somewhat narrower than previous ultrastructural determinations of the extent of microtubule overlap ($> 2 \mu\text{m}$)

(Mastronarde et al., 1993). Later in cleavage, both proteins localize to a discrete, central portion of the midbody. During interphase, some cells contain HsCYK-4 and MKLP1 in the nucleus, whereas others do not.

5 This is likely due to cell cycle regulated accumulation of these factors since, upon G2 arrest, HsCYK-4 and MKLP1 accumulate in the nucleus of all cells (data not shown). In addition, most cells contain brightly-

10 staining, cortical ring-like structures. These structures likely correspond to division remnants; previous time-lapse microscopy with GFP-tagged CYK-4 and ZEN-4 in nematode embryos revealed that the central spindle matures into the midbody that later develops into a persistent spot or ring in the cell cortex. Thus

15 there is a striking concordance between the biochemical properties and the subcellular localization of CYK-4/ZEN-4 in *C. elegans* embryos and HsCYK-4/MKLP1 in human cells. Since the names of the individual proteins vary from species to species, it is proposed to call

20 this complex "centralspindlin". It is reasonable to speculate that centralspindlin performs a similar function in these two systems.

To gain insight into the architecture of centralspindlin, the hydrodynamic properties of its

25 constituents were investigated. Lysates were prepared from mitotic HeLa cells and run on sucrose density gradients. Western blotting of the gradient fractions indicates that HsCYK-4 and MKLP1 precisely co-migrate on the gradients with an S-value of 8 S (fig. 17b).

30 This sedimentation behavior is similar to that of centralspindlin isolated from *C. elegans* embryos. The two proteins also co-migrated on a gel filtration

column with an apparent molecular weight of 800 kD (data not shown). Gel filtration chromatography can not accurately estimate native molecular mass of asymmetric particles, however, gel filtration data, combined with
5 S-value measurements, allows a more accurate estimation of the native molecular mass. When the experimental values of centralspindlin are combined in this way, the complex is estimated to have a native molecular weight of ~300 kDa.

10 To determine if equimolar amounts of HsCYK-4 and MKLP1 are present in centralspindlin and whether or not other proteins are also present, the complex was immunopurified from a mitotic MAP (microtubule-associated protein) fraction that was eluted with ATP
15 and 500 mM NaCl. Antibodies specific for HsCYK-4 and MKLP1 were used in parallel for the immunoprecipitation. Coomassie blue staining of both immunoprecipitates revealed two major bands and one minor band (fig. 17C). Mass spectrometry analysis
20 revealed that the slower migrating major band and the minor band are MKLP1 and the faster migrating major band is HsCYK-4. No additional bands reproducibly co precipitated with HsCYK-4 or MKLP1. Given that centralspindlin has a native molecular mass of 300 kD
25 and that it does not appear to contain any proteins in addition to HsCYK-4 (70 kD) and MKLP1 (100 kD) and given that both components are capable of self-association, it is concluded that centralspindlin is a tetramer containing two molecules each of HsCYK-4 and
30 MKLP1.

Figure 17 shows that there exists a complex of MKLP-1 and HsCYK-4 in HeLa cells

HsCYK-4/MgcRacGAP and MKLP-1, the human orthologs of CYK-4 and ZEN-4, respectively, exist as a complex in mitotic HeLa cells. (A) HsCYK-4 and MKLP-1 were immunoprecipitated from HeLa cell lysate with specific rabbit antibodies (IP:HsCYK-4 or MKLP-1) and blotted with specific mouse antibodies (blot: HsCYK-4 or MKLP-1). HsCYK-4 co-immunoprecipitated with MKLP-1 and vice versa. (B) HsCYK-4 and MKLP1 co-localize to the central spindle and the midbody. HeLa cells were fixed and immunostained with anti-CYK-4, anti-MKLP1, anti-tubulin antibodies and DNA was stained with Hoechst. Shown are cells in interphase (a) and various stages of cytokinesis (b-f). In main panels, staining of CYK-4 (green), microtubules (red) and DNA (blue) was shown. In inset, staining of CYK-4 (green) and MKLP1 (red) was shown. (C) HeLa cell lysates were analyzed by sucrose density gradient centrifugation followed by blotting with anti-MKLP-1 antibody or anti-HsCYK-4 antibody. HsCYK-4 and MKLP-1 co-sediment at 8S. The lowest band reacting with the CYK-4 antibody is caused by proteolysis of the N-terminus. (D) MKLP-1 and HsCYK-4 complex was immunoprecipitated from a microtubule-binding fraction (MTfr.) of mitotic HeLa cells with specific antibodies. Major 110 kDa and 75 kDa bands were identified by mass spectrometry as MKLP-1 and HsCYK-4, respectively. The minor band at 115 kDa also corresponds to MKLP1. Broad bands around 50 kDa and bands near gel bottom are heavy (IgGH) and light (IgGL) chains of immunoglobulin leaked from antibody beads.

Table 1

genotype	stage at time of shift to 25°C	percent viable	phenotype of surviving progeny	N
N2 (wild type)	embryos	98.8%	wild-type	485
<i>cyk-4</i>	(not shifted)	70.2%	fertile	198
<i>cyk-4</i>	embryos	1.5%	sterile, highly Unc	324
<i>cyk-4</i>	L1 larvae	100.0%	sterile, highly Unc	89
<i>cyk-4</i>	L2/L3	100.0%	sterile, highly Unc	55
<i>cyk-4</i>	L4	100.0%	fertile, lay dead embryos	52
<i>cyk-4</i> , <i>xSEx1[cyk- 4:GFP]</i>	embryos	59.4%	fertile	350

- 5 Except for the N2 control, the complete genotype of the strain was *unc-32(e189) cyk-4(t1689ts)*. Gravid hermaphrodites were allowed to lay embryos for 2 hours at the permissive temperature. The adult was then removed and the number of embryos counted. After 24
- 10 hours at the indicated temperature the number of unhatched embryos was then counted.

Table 2

injected locus dsRNA	percent cytokinesis defective (N)	number of time lapse recording s	number cytokinesis s defective	additional phenotypes
RhoA Y51H4A.B	95% (175)	15	15 (100%)	
Rac-1 C09G12.8 B	Not emb. lethal	5	0	
Cdc42 R07G3.1	12% (74)	22	3 (14%)	symmetric 1st division (5/22); no rotation in P1 (12/22); rotation of AB (2/22)
others F22E12.2	Not emb. lethal			
Y32F6B.3	Not emb. lethal			
K03D3.9	Not emb. lethal			

Young adult hermaphrodites were injected with the

5 indicated dsRNAs and broods of laid embryos were scored
for embryonic lethality. dsRNAs that induced embryonic
lethality were further characterized by dissecting
embryos and scoring for multinucleate embryos and by
performing time lapse recordings and evaluating

10 cytokinesis, spindle orientation in the one-cell embryo
(symmetric or asymmetric first cleavage), and spindle
positioning in the P1 and AB blastomeres.

Table 3

genotype	temperature	total number of stained remnants	total number of cells	average number of remnants/ cell	number embry
N2 (wildtype)	25°C	110	137	0.80	16
<i>zen-4(or198ts)</i>	16°C	61	83	0.73	10
<i>zen-4(or198ts)</i>	25°C (18 min.)	11	147	0.07	24
N2 (wildtype)	25°C	150	205	0.73	22
<i>cyk-4(t1689ts)</i>	16°C	61	98	0.62	10
<i>cyk-4(t1689ts)</i>	25°C (15 min.)	10	176	0.06	19

Wild-type and *zen-4(or153ts)* embryos grown at the
 5 indicated temperatures were fixed and stained for
 Cyk-4. Similarly, Wild-type and *cyk-4(t1689ts)* grown
 at the indicated temperatures were fixed and stained
 for Zen-4/CeMKlp1. The number of cells in each embryo and
 the number of remnants staining with Cyk-4 or Zen-4
 10 antibodies was counted.

References

- Adams, R. R., Tavares, A. A., Salzberg, A., Bellen, H.
5 J., and Glover, D. M. (1998). pavarotti encodes a
kinesin-like protein required to organize the
central spindle and contractile ring for
cytokinesis. *Genes Dev* 12, 1483-94.
- Aktories, K., and Hall, A. (1989). Botulinum ADP-
10 ribosyltransferase C3: a new tool to study low
molecular weight GTP-binding proteins. *Trends
Pharmacol Sci* 10, 415-8.
- Bosher, J.M. and Labouesse, M., (2000), *Nat Cell Biol*,
Feb; 2(2):E31-6
- 15 Busson, S., Dujardin, D., Moreau, A., Dompierre, J.,
and De Mey, J. R. (1998). Dynein and dynactin are
localized to astral microtubules and at cortical
sites in mitotic epithelial cells. *Curr Biol* 8,
541-4.
- 20 Cao, L. G., and Wang, Y. L. (1996). Signals from the
spindle midzone are required for the stimulation
of cytokinesis in cultured epithelial cells. *Mol
Biol Cell* 7, 225-32.
- Carmena, M., Riparbelli, M. G., Minestrini, G.,
25 Tavares, A. M., Adams, R., Callaini, G., and
Glover, D. M. (1998). *Drosophila* polo kinase is
required for cytokinesis. *J Cell Biol* 143, 659-71.
- Carminati, J. L., and Stearns, T. (1997). Microtubules
orient the mitotic spindle in yeast through
30 dynein- dependent interactions with the cell
cortex. *J Cell Biol* 138, 629-41.

- Case, R. B., Rice, S., Hart, C. L., Ly, B., and Vale, R. D. (2000). Role of the kinesin neck linker and catalytic core in microtubule-based motility. *Curr Biol* 10, 157-60.
- 5 Castrillon, D. H., and Wasserman, S. A. (1994). Diaphanous is required for cytokinesis in *Drosophila* and shares domains of similarity with the products of the limb deformity gene. *Development* 120, 3367-77.
- 10 Chang, F., Drubin, D., and Nurse, P. (1997). *cdc12p*, a protein required for cytokinesis in fission yeast, is a component of the cell division ring and interacts with profilin. *J Cell Biol* 137, 169-82.
- 15 Chui, K. K., Rogers, G. C., Kashina, A. M., Wedaman, K. P., Sharp, D. J., Nguyen, D. T., Wilt, F., and Scholey, J. M. (2000). Roles of two homotetrameric kinesins in sea urchin embryonic cell division. *J Biol Chem* 275, 38005-11.
- 20 Drechsel, D. N., Hyman, A. A., Hall, A., and Glotzer, M. (1997). A requirement for Rho and Cdc42 during cytokinesis in *Xenopus* embryos. *Curr Biol* 7, 12-23.
- 25 Dutartre, H., Davoust, J., Gorvel, J. P., and Chavrier, P. (1996). Cytokinesis arrest and redistribution of actin-cytoskeleton regulatory components in cells expressing the Rho GTPase CDC42Hs. *J Cell Sci* 109, 367-77.
- 30 Echard, A., Jollivet, F., Martinez, O., Lacapere, J. J., Rousselet, A., Janoueix-Lerosey, I., and Goud, B. (1998). Interaction of a Golgi-associated kinesin-like protein with Rab6. *Science* 279, 580-5.

- Eckley, D. M., Ainsztein, A. M., Mackay, A. M.,
Goldberg, I. G., and Earnshaw, W. C. (1997).
Chromosomal proteins and cytokinesis: patterns of
cleavage furrow formation and inner centromere
protein positioning in mitotic heterokaryons and
5 mid-anaphase cells. *J Cell Biol* 136, 1169-83.
- Evangelista, M., Blundell, K., Longtine, M. S., Chow,
C. J., Adames, N., Pringle, J. R., Peter, M., and
Boone, C. (1997). Bni1p, a yeast formin linking
10 cdc42p and the actin cytoskeleton during polarized
morphogenesis. *Science* 276, 118-22.
- Field, C., Li, R., and Oegema, K. (1999). Cytokinesis
in eukaryotes: a mechanistic comparison. *Curr Opin*
Cell Biol 11, 68-80.
- 15 Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A.,
Driver, S. E., and Mello, C. C. (1998). Potent and
specific genetic interference by double-stranded
RNA in *Caenorhabditis elegans*. *Nature* 391, 806-11.
- Fire, A., (1999), *Trends Genet*, Sep; 15(9):358-63
- 20 Fontijn, R. D., Goud, B., Echard, A., Jollivet, F., van
Marle, J., Pannekoek, H., and Horrevoets, A. J.
(2001). The Human Kinesin-Like Protein RB6K Is
under Tight Cell Cycle Control and Is Essential
for Cytokinesis. *Mol Cell Biol* 21, 2944-55.
- 25 Fujiwara, T., Tanaka, K., Inoue, E., Kikyo, M., and
Takai, Y. (1999). Bni1p Regulates Microtubule-
Dependent Nuclear Migration through the Actin
Cytoskeleton in *Saccharomyces cerevisiae*. *Mol Cell*
Biol 19, 8016-8027.
- 30 Giansanti, M. G., Bonaccorsi, S., Williams, B.,
Williams, E. V., Santolamazza, C., Goldberg, M.
L., and Gatti, M. (1998). Cooperative interactions

- between the central spindle and the contractile ring during *Drosophila* cytokinesis. *Genes Dev* 12, 396-410.
- 5 Glotzer, M. (1997). The mechanism and control of cytokinesis. *Curr Opin Cell Biol* 9, 815-23.
- Glotzer, M. (1997). Cytokinesis. *Curr Biol* 7, R274-6.
- Gönczy, P., Pichler, S., Kirkham, M., and Hyman, A. A. (1999a). Cytoplasmic dynein is required for distinct aspects of MTOC positioning, including
10 centrosome separation, in the one cell stage *Caenorhabditis elegans* embryo. *J Cell Biol* 147, 135-50.
- Gönczy, P., Schnabel, H., Kaletta, T., Amores, A. D., Hyman, T., and Schnabel, R. (1999b). Dissection of
15 cell division processes in the one cell stage *Caenorhabditis elegans* embryo by mutational analysis. *J Cell Biol* 144, 927-46.
- Hill, E., Clarke, M., and Barr, F. A. (2000). The Rab6-binding kinesin, Rab6-KIFL, is required for
20 cytokinesis. *Embo J* 19, 5711-9.
- Hirose, K., Kawashima, T., Iwamoto, I., Nosaka, T., and Kitamura, T. (2001). MgcRacGAP is involved in cytokinesis through associating with mitotic spindle and midbody. *J Biol Chem* 276, 5821-8.
- 25 Hurley, J. H., and Meyer, T. (2001). Subcellular targeting by membrane lipids. *Curr Opin Cell Biol* 13, 146-52.
- Hyman, A. A., and White, J. G. (1987). Determination of cell division axes in the early embryogenesis of
30 *Caenorhabditis elegans*. *J Cell Biol* 105, 2123-35.

- Hyman, A. A. (1989). Centrosome movement in the early divisions of *Caenorhabditis elegans*: a cortical site determining centrosome position. *J Cell Biol* 109, 1185-93.
- 5 Imamura, H., Tanaka, K., Hihara, T., Umikawa, M., Kamei, T., Takahashi, K., Sasaki, T., and Takai, Y. (1997). Bnlp and Bnrlp: downstream targets of the Rho family small G-proteins which interact with profilin and regulate actin cytoskeleton in
- 10 *Saccharomyces cerevisiae*. *Embo J* 16, 2745-55.
- Jantsch-Plunger, V., and Glotzer, M. (1999). Depletion of syntaxins in the early *Caenorhabditis elegans* embryo reveals a role for membrane fusion events in cytokinesis. *Curr Biol* 9, 738-45.
- 15 Jantsch-Plunger, V., Gonczy, P., Romano, A., Schnabel, H., Hamill, D., Schnabel, R., Hyman, A. A., and Glotzer, M. (2000). CYK-4. A rho family gtpase activating protein (gap) required for central spindle formation and cytokinesis. *J Cell Biol*
- 20 149, 1391-404.
- Kaitna, S., Mendoza, M., Jantsch-Plunger, V., and Glotzer, M. (2000). Incenp and an aurora-like kinase form a complex essential for chromosome segregation and efficient completion of
- 25 cytokinesis [In Process Citation]. *Curr Biol* 10, 1172-81.
- Kishi, K., Sasaki, T., Kuroda, S., Itoh, T., and Takai, Y. (1993). Regulation of cytoplasmic division of *Xenopus* embryo by rho p21 and its inhibitory
- 30 GDP/GTP exchange protein (rho GDI). *J Cell Biol* 120, 1187-95.

- Kosako, H., Goto, H., Yanagida, M., Matsuzawa, K.,
Fujita, M., Tomono, Y., Okigaki, T., Odai, H.,
Kaibuchi, K., and Inagaki, M. (1999). Specific
accumulation of Rho-associated kinase at the
5 cleavage furrow during cytokinesis: cleavage
furrow-specific phosphorylation of intermediate
filaments. *Oncogene* 18, 2783-8.
- Kull, F. J., Sablin, E. P., Lau, R., Fletterick, R. J.,
and Vale, R. D. (1996). Crystal structure of the
10 kinesin motor domain reveals a structural
similarity to myosin. *Nature* 380, 550-5.
- Kuriyama, R., Dragas-Granoic, S., Maekawa, T.,
Vassilev, A., Khodjakov, A., and Kobayashi, H.
(1994). Heterogeneity and microtubule interaction
15 of the CHO1 antigen, a mitosis-specific kinesin-
like protein. Analysis of subdomains expressed in
insect sf9 cells. *J Cell Sci* 107, 3485-99.
- Lamarche, N., and Hall, A. (1994). GAPs for rho-related
GTPases. *Trends Genet* 10, 436-40.
- 20 Larkin, K., and Danilchik, M.V. (1999), *Dev Biol.*
214:215-226
- Lee, K. S., Yuan, Y. L., Kuriyama, R., and Erikson, R.
L. (1995). Plk is an M-phase-specific protein
kinase and interacts with a kinesin- like protein,
25 CHO1/MKLP-1. *Mol Cell Biol* 15, 7143-51.
- Lewis, J. A., and Fleming, J. T. (1995). Basic culture
methods. *Methods Cell Biol* 48, 13-29.
- Mabuchi, I., Hamaguchi, Y., Fujimoto, H., Morii, N.,
Mishima, M., and Narumiya, S. (1993). A rho-like
30 protein is involved in the organisation of the
contractile ring in dividing sand dollar eggs.
Zygote 1, 325-31.

- Mackay, A. M., Ainsztein, A. M., Eckley, D. M., and Earnshaw, W. C. (1998). A dominant mutant of inner centromere protein (INCENP), a chromosomal protein, disrupts prometaphase congression and cytokinesis. J Cell Biol 140, 991-1002.
- 5 Martineau-Thuillier, S., Andreassen, P. R., and Margolis, R. L. (1998). Colocalization of TD-60 and INCENP throughout G2 and mitosis: evidence for their possible interaction in signalling
- 10 cytokinesis. Chromosoma 107, 461-70.
- Mastronarde, D. N., McDonald, K. L., Ding, R., and McIntosh, J. R. (1993). Interpolar spindle microtubules in PTK cells. J Cell Biol 123, 1475-89.
- 15 Mello, C. C., Kramer, J. M., Stinchcomb, D., and Ambros, V. (1991). Efficient gene transfer in C.elegans: extrachromosomal maintenance and integration of transforming sequences. Embo J 10, 3959-70.
- 20 Miller, R. K., Matheos, D., and Rose, M. D. (1999). The cortical localization of the microtubule orientation protein, Kar9p, is dependent upon actin and proteins required for polarization. J Cell Biol 144, 963-75.
- 25 Moorman, J. P., Bobak, D. A., and Hahn, C. S. (1996). Inactivation of the small GTP binding protein Rho induces multinucleate cell formation and apoptosis in murine T lymphoma EL4. J Immunol 156, 4146-53.
- Nislow, C., Lombillo, V. A., Kuriyama, R., and
- 30 McIntosh, J. R. (1992). A plus-end-directed motor enzyme that moves antiparallel microtubules in

- vitro localizes to the interzone of mitotic
spindles. *Nature* 359, 543-7.
- O'Connell, C. B., Wheatley, S. P., Ahmed, S., and Wang,
Y. L. (1999). The small GTP-binding protein rho
5 regulates cortical activities in cultured cells
during division. *J Cell Biol* 144, 305-13.
- O'Connell, K. F., Leys, C. M., and White, J. G. (1998).
A genetic screen for temperature-sensitive cell-
division mutants of *Caenorhabditis elegans*.
10 *Genetics* 149, 1303-21.
- Okada, Y., and Hirokawa, N. (2000). Mechanism of the
single-headed processivity: diffusional anchoring
between the K-loop of kinesin and the C terminus
of tubulin. *Proc Natl Acad Sci U S A* 97, 640-5.
- 15 Powers, J., Bossinger, O., Rose, D., Strome, S., and
Saxton, W. (1998). A nematode kinesin required for
cleavage furrow advancement. *Curr Biol* 8, 1133-6.
- Prokopenko, S. N., Brumby, A., O'Keefe, L., Prior, L.,
He, Y., Saint, R., and Bellen, H. J. (1999). A
20 putative exchange factor for Rho1 GTPase is
required for initiation of cytokinesis in
Drosophila. *Genes Dev* 13, 2301-14.
- Raich, W. B., Moran, A. N., Rothman, J. H., and Hardin,
J. (1998). Cytokinesis and midzone microtubule
25 organization in *Caenorhabditis elegans* require the
kinesin-like protein ZEN-4. *Mol Biol Cell* 9,
2037-49.
- Rappaport, R. (1985). Repeated furrow formation from a
single mitotic apparatus in cylindrical sand
30 dollar eggs. *J Exp Zool* 234, 167-71.
- Reddien, P., and Horvitz, H. (2000). CED-2/CrkII and
CED-10/Rac control phagocytosis and cell migration

in *Caenorhabditis elegans*. *Nature Cell Biology* 2,
131-136.

Remington's Pharmaceutical Sciences, 1980, Mack Publ.
Co. Easton, PA, Osol (ed.)

5

Remington: The Science and Practice of Pharmacy, 2000
(20th edition; Book News, Inc.)

Rice, S., Lin, A. W., Safer, D., Hart, C. L., Naber,
N., Carragher, B. O., Cain, S. M., Pechatnikova,
10 E., Wilson-Kubalek, E. M., Whittaker, M., Pate,
E., Cooke, R., Taylor, E. W., Milligan, R. A., and
Vale, R. D. (1999). A structural change in the
kinesin motor protein that drives motility. *Nature*
402, 778-84.

15 Rieder, C. L., Khodjakov, A., Paliulis, L. V., Fortier,
T. M., Cole, R. W., and Sluder, G. (1997). Mitosis
in vertebrate somatic cells with two spindles:
implications for the metaphase/anaphase transition
checkpoint and cleavage. *Proc Natl Acad Sci U S A*
20 94, 5107-12.

Sablin, E. P., Kull, F. J., Cooke, R., Vale, R. D., and
Fletterick, R. J. (1996). Crystal structure of the
motor domain of the kinesin-related motor ncd.
Nature 380, 555-9.

25 Sambrook et al., 2000, *Molecular Cloning*, Third Edition
Savoian, M. S., Earnshaw, W. C., Khodjakov, A., and
Rieder, C. L. (1999). Cleavage furrows formed
between centrosomes lacking an intervening spindle
and chromosomes contain microtubule bundles,
30 INCENP, and CHO1 but not CENP-E. *Mol Biol Cell* 10,
297-311.

- Saxton, W. M., and McIntosh, J. R. (1987). Interzone microtubule behavior in late anaphase and telophase spindles. *J Cell Biol* 105, 875-86.
- Schumacher, J. M., Golden, A., and Donovan, P. J.
5 (1998). AIR-2: An Aurora/Ipl1-related protein kinase associated with chromosomes and midbody microtubules is required for polar body extrusion and cytokinesis in *Caenorhabditis elegans* embryos. *J Cell Biol* 143, 1635-46.
- 10 Settleman, J., and Foster, R., (1995), *Methods Enzymol*; 256:105-13
- Severson, A. F., Schumacher, J., Hamill, D. R., Carter, J. C., and Bowerman, B. (2000). The Aurora/Ipl1p-Related Kinase AIR-2 Functions at Metaphase to
15 Recruit the Kinesin-like Protein ZEN-4 to the Mitotic Spindle Midzone and is Required for Cytokinesis. *Current Biology*, Oct 5;10(19): 1162-71.
- Sharp, D. J., Kuriyama, R., and Baas, P. W. (1996).
20 Expression of a kinesin-related motor protein induces Sf9 cells to form dendrite-like processes with nonuniform microtubule polarity orientation. *J Neurosci* 16, 4370-5.
- Sharp, P.A., (1999), *Genes Dev*, Jan 15; 13(2):139-41
- 25 Skop, A. R., and White, J. G. (1998). The dynactin complex is required for cleavage plane specification in early *Caenorhabditis elegans* embryos. *Curr Biol* 8, 1110-6.
- Sugihara, K., Nakatsuji, N., Nakamura, K., Nakao, K.,
30 Hashimoto, R., Otani, H., Sakagami, H., Kondo, H., Nozawa, S., Aiba, A., and Katsuki, M. (1998). Rac1

is required for the formation of three germ layers during gastrulation. *Oncogene* 17, 3427-33.

- Sulston, J.E., and Horvitz, H.R., (1977), *Dev Biol.* 56:110-156
- 5 Swan, K. A., Severson, A. F., Carter, J. C., Martin, P. R., Schnabel, H., Schnabel, R., and Bowerman, B. (1998). *cyk-1*: a *C. elegans* FH gene required for a late step in embryonic cytokinesis. *J Cell Sci* 111, 2017-27.
- 10 Tatsumoto, T., Xie, X., Blumenthal, R., Okamoto, I., and Miki, T. (1999). Human ECT2 is an exchange factor for rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis [In Process Citation]. *J Cell Biol* 147, 921-8.
- 15 Timmons, L., and Fire, A. (1998). Specific interference by ingested dsRNA. *Nature* 395, 854.
- Toure, A., Dorseuil, O., Morin, L., Timmons, P., Jegou, B., Reibel, L., and Gacon, G. (1998). MgcRacGAP, a new human GTPase-activating protein for Rac and
- 20 Cdc42 similar to *Drosophila* rotundRacGAP gene product, is expressed in male germ cells. *J Biol Chem* 273, 6019-23.
- Vale, R. D., and Fletterick, R. J. (1997). The design plan of kinesin motors. *Annu Rev Cell Dev Biol* 13,
- 25 745-77.
- Vale, R. D., and Milligan, R. A. (2000). The way things move: looking under the hood of molecular motor proteins. *Science* 288, 88-95.

- Van Aelst, L., and D'Souza-Schorey, C. (1997). Rho GTPases and signaling networks. *Genes Dev* 11,2295-322.
- 5 Van de Putte T, Zwijsen A, Lonnoy O, Rybin V, Cozijnsen M, Francis A, Baekelandt V, Kozak CA, Zerial M, Huylebroeck D. Mice with a homozygous gene trap vector insertion in *mgcRacGAP* die during pre-implantation development. *Mech Dev.* 2001 Apr;102(1-2):33-44
- 10 Waddle, J. A., Cooper, J. A., and Waterston, R. H. (1994). Transient localized accumulation of actin in *Caenorhabditis elegans* blastomeres with oriented asymmetric divisions. *Development* 120, 2317-28.
- 15 Watanabe, N., Madaule, P., Reid, T., Ishizaki, T., Watanabe, G., Kakizuka, A., Saito, Y., Nakao, K., Jockusch, B. M., and Narumiya, S. (1997). *p140mDia*, a mammalian homolog of *Drosophila* *diaphanous*, is a target protein for Rho small GTPase and is a ligand for profilin. *Embo J* 16, 3044-56.
- 20 Wheatley, S. P., and Wang, Y. L. (1996). Midzone microtubules are continuously required for cytokinesis in cultured epithelial cells. *J. Cell Biol.* 135, 981-989.
- 25 Woollard, A., and Hodgkin, J. (1999). *Stu-7/air-2* is a *C. elegans* aurora homologue essential for chromosome segregation during embryonic and post-embryonic development. *Mech Dev* 82, 95-108.
- 30

Claims

1. Human polypeptide designated Cyk-4, which is a
GTPase activating protein (GAP) for Rho family of
5 GTPases, with the amino acid sequence as set forth
in SEQ ID NO:2 or with the amino acid sequence
encoded by a polynucleotide which hybridizes under
stringent conditions to a polynucleotide having a
nucleotide sequence as set forth in SEQ ID NO:1.
- 10 2. Murine Cyk-4 polypeptide designated Cyk-4, which is
a GTPase activating protein (GAP) for Rho family of
GTPases, with the amino acid sequence as set forth
in SEQ ID NO:4 or with the amino acid sequence
15 encoded by a polynucleotide which hybridizes under
stringent conditions to a polynucleotide having a
nucleotide sequence as set forth in SEQ ID NO:3.
3. An isolated DNA molecule comprising a
polynucleotide with the nucleotide sequence as set
forth in SEQ ID NO:1 encoding human Cyk-4
20 polypeptide, or an isolated DNA molecule encoding
human Cyk-4 polypeptide comprising a polynucleotide
which hybridizes under stringent conditions to a
polynucleotide having a nucleotide sequence as set
forth in SEQ ID NO:1.
- 25 4. An isolated DNA molecule comprising a
polynucleotide with the nucleotide sequence as set
forth in SEQ ID NO:3 encoding murine Cyk-4
polypeptide, or an isolated DNA molecule encoding
murine Cyk-4 polypeptide comprising a
30 polynucleotide which hybridizes under stringent

conditions to a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO:3.


5. An antibody which is specifically reactive with an epitope of the human Cyk-4 polypeptide of claim 1.
- 5 6. An antibody which is specifically reactive with an epitope of the murine Cyk-4 polypeptide of claim 2.
7. A method for identifying a compound capable of modulating cytokinesis, wherein the compound's ability to modulate the function of CYK-4 is
10 determined.
8. The method of claim 7 wherein the compound's ability to promote GTP hydrolysis by a Rho family GTPase is determined by incubating a substrate selected from the members of the Rho family GTPases
15 with GTP for a period of time sufficient to allow saturation of the substrate's GTP binding sites, adding Cyk-4 and allowing it to react in the presence or absence of the test compound, and determining the amount of hydrolyzed GTP.
- 20 9. The method of claim 7 wherein the compound's ability to inhibit Cyk-4 function is determined by determining the compound's ability to interfere with the biochemical interaction of CYK-4 and a member of the MKLP1 subfamily.
- 25 10. The method of claim 7 wherein the compound's ability to inhibit CYK-4 function is determined by determining the compound's ability to interfere with the biochemical multimerization of CYK-4.

11. The method of claim 7 wherein the compound's
ability to inhibit MKLP1 function is determined by
determining the compound's ability to interfere
with the biochemical multimerization of a member of
5 the MKLP1 subfamily.
12. A compound identified in the method of any one of
claims 7 to 11 for use in cancer therapy.


1/32
Fig. 1




2/32
Fig. 2




3/32
Fig. 3 A,B,C



4/32
Fig. 3D




5/32
Fig. 4



6/32


Fig. 5




7/32
Fig. 6




8/32
Fig. 7




9/32
Fig. 8



10/32
Fig. 9




11/32
Fig. 10




12/32
Fig. 11

rhoA (RNAi)




wt




13/32
Fig. 12 A

A




14/32
Fig. 12 B

B




15/32
Fig. 12 C

C




16/32
Fig. 13 A




17/32
Fig. 13 B

B




18/32
Fig. 13 C

C




19/32
Fig. 13 D


D




20/32
Fig. 14 A




21/32
Fig. 14 B




22/32
Fig. 14 C



23/32
Fig. 15 A




24/32
Fig. 15 B




25/32
Fig. 15 C

C




26/32
Fig. 16 A

A




B


27/32
Fig. 16 B



28/32
Fig. 17 A




29/32
Fig. 17 B




B

30/32
Fig. 17 C




31/32
Fig. 17 D

D



32/32
Fig. 18



SEQUENCE LISTING

<110> Boehringer Ingelheim International GmbH .

<120> Cyk-4 polypeptides, DNA molecules encoding them and their use in screening methods

<130> Case 14/057,063

<140>

<141>

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 3050

<212> DNA

<213> Homo sapiens

<220>

<221> 5'UTR

<222> (1)..(70)

<220>

<221> CDS

<222> (71)..(1969)

<220>

<221> 3'UTR

<222> (1970)..(3050)

<400> 1

taaagggggg tgccagacca ggtgctctg ccgctggatt gtgataggaa gcagagtgtt 60

cgtgtgaaag atg gat act atg atg ctg aat gtg cgg aat ctg ttt gag 109
Met Asp Thr Met Met Leu Asn Val Arg Asn Leu Phe Glu
1 5 10

cag ctt gtg cgc cgg gtg gag att ctc agt gaa gga aat gaa gtc caa 157
Gln Leu Val Arg Arg Val Glu Ile Leu Ser Glu Gly Asn Glu Val Gln
15 20 25

ttt atc cag ttg gcg aag gac ttt gag gat ttc cgt aaa aag tgg cag 205
Phe Ile Gln Leu Ala Lys Asp Phe Glu Asp Phe Arg Lys Lys Trp Gln
30 35 40 45

agg act gac cat gag ctg ggg aaa tac aag gat ctt ttg atg aaa gca 253
Arg Thr Asp His Glu Leu Gly Lys Tyr Lys Asp Leu Leu Met Lys Ala
50 55 60

gag act gag cga agt gct ctg gat gtt aag ctg aag cat gca cgt aat	301
Glu Thr Glu Arg Ser Ala Leu Asp Val Lys Leu Lys His Ala Arg Asn	
65 70 75	
cag gtg gat gta gag atc aaa cgg aga cag aga gct gag gct gac tgc	349
Gln Val Asp Val Glu Ile Lys Arg Arg Gln Arg Ala Glu Ala Asp Cys	
80 85 90	
gaa aag ctg gaa cga cag att cag ctg att cga gag atg ctc atg tgt	397
Glu Lys Leu Glu Arg Gln Ile Gln Leu Ile Arg Glu Met Leu Met Cys	
95 100 105	
gac aca tct ggc agc att caa cta agc gag gag caa aaa tca gct ctg	445
Asp Thr Ser Gly Ser Ile Gln Leu Ser Glu Glu Gln Lys Ser Ala Leu	
110 115 120 125	
gct ttt ctc aac aga ggc caa cca tcc agc agc aat gct ggg aac aaa	493
Ala Phe Leu Asn Arg Gly Gln Pro Ser Ser Ser Asn Ala Gly Asn Lys	
130 135 140	
aga cta tca acc att gat gaa tct ggt tcc att tta tca gat atc agc	541
Arg Leu Ser Thr Ile Asp Glu Ser Gly Ser Ile Leu Ser Asp Ile Ser	
145 150 155	
ttt gac aag act gat gaa tca ctg gat tgg gac tct tct ttg gtg aag	589
Phe Asp Lys Thr Asp Glu Ser Leu Asp Trp Asp Ser Ser Leu Val Lys	
160 165 170	
act ttc aaa ctg aag aag aga gaa aag agg cgc tct act agc cga cag	637
Thr Phe Lys Leu Lys Lys Arg Glu Lys Arg Arg Ser Thr Ser Arg Gln	
175 180 185	
ttt gtt gat ggt ccc cct gga cct gta aag aaa act cgt tcc att ggc	685
Phe Val Asp Gly Pro Pro Gly Pro Val Lys Lys Thr Arg Ser Ile Gly	
190 195 200 205	
tct gca gta gac cag ggg aat gaa tcc ata gtt gca aaa act aca gtg	733
Ser Ala Val Asp Gln Gly Asn Glu Ser Ile Val Ala Lys Thr Thr Val	
210 215 220	
act gtt ccc aat gat ggc ggg ccc atc gaa gct gtg tcc act att gag	781
Thr Val Pro Asn Asp Gly Gly Pro Ile Glu Ala Val Ser Thr Ile Glu	
225 230 235	
act gtg cca tat tgg acc agg agc cga agg aaa aca ggt act tta caa	829
Thr Val Pro Tyr Trp Thr Arg Ser Arg Arg Lys Thr Gly Thr Leu Gln	
240 245 250	
cct tgg aac agt gac tcc acc ctg aac agc agg cag ctg gag cca aga	877
Pro Trp Asn Ser Asp Ser Thr Leu Asn Ser Arg Gln Leu Glu Pro Arg	
255 260 265	
act gag aca gac agt gtg ggc acg cca cag agt aat gga ggg atg cgc	925
Thr Glu Thr Asp Ser Val Gly Thr Pro Gln Ser Asn Gly Gly Met Arg	
270 275 280 285	

ctg cat gac ttt gtt tct aag acg gtt att aaa cct gaa tcc tgt gtt	973
Leu His Asp Phe Val Ser Lys Thr Val Ile Lys Pro Glu Ser Cys Val	
290 295 300	
cca tgt gga aag cgg ata aaa ttt ggc aaa tta tct ctg aag tgt cga	1021
Pro Cys Gly Lys Arg Ile Lys Phe Gly Lys Leu Ser Leu Lys Cys Arg	
305 310 315	
gac tgt cgt gtg gtc tct cat cca gaa tgt cgg gac cgc tgt ccc ctt	1069
Asp Cys Arg Val Val Ser His Pro Glu Cys Arg Asp Arg Cys Pro Leu	
320 325 330	
ccc tgc att cct acc ctg ata gga aca cct gtc aag att gga gag gga	1117
Pro Cys Ile Pro Thr Leu Ile Gly Thr Pro Val Lys Ile Gly Glu Gly	
335 340 345	
atg ctg gca gac ttt gtg tcc cag act tct cca atg atc ccc tcc att	1165
Met Leu Ala Asp Phe Val Ser Gln Thr Ser Pro Met Ile Pro Ser Ile	
350 355 360 365	
gtt gtg cat tgt gta aat gag att gag caa aga ggt ctg act gag aca	1213
Val Val His Cys Val Asn Glu Ile Glu Gln Arg Gly Leu Thr Glu Thr	
370 375 380	
ggc ctg tat agg atc tct ggc tgt gac cgc aca gta aaa gag ctg aaa	1261
Gly Leu Tyr Arg Ile Ser Gly Cys Asp Arg Thr Val Lys Glu Leu Lys	
385 390 395	
gag aaa ttc ctc aga gtg aaa act gta ccc ctc ctc agc aaa gtg gat	1309
Glu Lys Phe Leu Arg Val Lys Thr Val Pro Leu Leu Ser Lys Val Asp	
400 405 410	
gat atc cat gct atc tgt agc ctt cta aaa gac ttt ctt cga aac ctc	1357
Asp Ile His Ala Ile Cys Ser Leu Leu Lys Asp Phe Leu Arg Asn Leu	
415 420 425	
aaa gaa cct ctt ctg acc ttt cgc ctt aac aga gcc ttt atg gaa gca	1405
Lys Glu Pro Leu Leu Thr Phe Arg Leu Asn Arg Ala Phe Met Glu Ala	
430 435 440 445	
gca gaa atc aca gat gaa gac aac agc ata gct gcc atg tac caa gct	1453
Ala Glu Ile Thr Asp Glu Asp Asn Ser Ile Ala Ala Met Tyr Gln Ala	
450 455 460	
gtt ggt gaa ctg ccc cag gcc aac agg gac aca tta gct ttc ctc atg	1501
Val Gly Glu Leu Pro Gln Ala Asn Arg Asp Thr Leu Ala Phe Leu Met	
465 470 475	
att cac ttg cag aga gtg gct cag agt cca cat act aaa atg gat gtt	1549
Ile His Leu Gln Arg Val Ala Gln Ser Pro His Thr Lys Met Asp Val	
480 485 490	
gcc aat ctg gct aaa gtc ttt ggc cct aca ata gtg gcc cat gct gtg	1597
Ala Asn Leu Ala Lys Val Phe Gly Pro Thr Ile Val Ala His Ala Val	
495 500 505	

ccc aat cca gac cca gtg aca atg tca cag gac atc aag cgt caa ccc	1645
Pro Asn Pro Asp Pro Val Thr Met Ser Gln Asp Ile Lys Arg Gln Pro	
510 515 520 525	
aag gtg gtt gag cgc ctg ctt tcc ttg cct ctg gag tat tgg agt cag	1693
Lys Val Val Glu Arg Leu Leu Ser Leu Pro Leu Glu Tyr Trp Ser Gln	
530 535 540	
ttc atg atg gtg gag caa gag aac att gac ccc cta cat gtc att gaa	1741
Phe Met Met Val Glu Gln Glu Asn Ile Asp Pro Leu His Val Ile Glu	
545 550 555	
aac tca aat gcc ttt tca aca cca cag aca cca gat att aaa gtg agt	1789
Asn Ser Asn Ala Phe Ser Thr Pro Gln Thr Pro Asp Ile Lys Val Ser	
560 565 570	
tta ctg gga cct gtg acc act cct gaa cat cag ctt ctc aag act cct	1837
Leu Leu Gly Pro Val Thr Thr Pro Glu His Gln Leu Leu Lys Thr Pro	
575 580 585	
tca tct agt tcc ctg tca cag aga gtc cgt tcc acc ctc acc aag aac	1885
Ser Ser Ser Ser Leu Ser Gln Arg Val Arg Ser Thr Leu Thr Lys Asn	
590 595 600 605	
act cct aga ttt ggg agc aaa agc aag tct gcc act aac cta gga cga	1933
Thr Pro Arg Phe Gly Ser Lys Ser Lys Ser Ala Thr Asn Leu Gly Arg	
610 615 620	
caa ggc aac ttt ttt gct tct cca atg ctc aag tga agtcacatct	1979
Gln Gly Asn Phe Phe Ala Ser Pro Met Leu Lys	
625 630	
gcctgttact tcccagcatt gactgactat aagaaaggac acatctgtac tctgctctgc	2039
agcctcctgt actcattact acttttagca ttctccaggc ttttactcaa gtttaattgt	2099
gcatgaggggt tttattaaaa ctatatatat ctccccttcc ttctcctcaa gtcacataat	2159
atcagcaactt tgtgctgggc attgttggga gcttttagat gagacatctt tccaggggta	2219
gaagggtttag tatggaattg gttgtgattc tttttgggga agggggttat tgttcctttg	2279
gcttaaagcc aaatgctgct catagaatga tctttctcta gtttcattta gaactgattt	2339
ccgtgagaca atgacagaaa ccctacctat ctgataagat tagcttgtct caggggtggga	2399
agtgaggagg cagggcaaag aaaggattag accagaggat ttaggatgcc tccttctaag	2459
aaccagaagt tctcattccc cattatgaac tgagctataa tatggagctt tcataaaaat	2519
gggatgcatt gaggacagaa ctagtgatgg gagtatgcgt agctttgatt tggatgatta	2579
ggcttttaaat agtgttgagt ggcacaacct tgtaaattgt aaagtacaac tcgtatttat	2639
ctctgatgtg ccgctggctg aactttgggt tcatttgggg tcaaagccag tttttctttt	2699
aaaattgaat tcattctgat gcttgcccc catacccca accttgtcca gtggagccca	2759

acttctaaag gtcaatatat catccttttg catcccaact accaataaag agtaggctat 2819
aaggggaagat tgtcaatatt ttgtggtaag aaaagctaca gtcatttttt ctttgcactt 2879
tg gatgctga aatttttccc atggaacata gccacatcta gatagatgtg agcttttttct 2939
tctgttaaaa ttattcttaa tgtctgtaaa aacgattttc ttctgtagaa tg ttttgactt 2999
cgtattgacc cttatctgta aaacacctat ttgggataat atttggcttt a 3050

<210> 2

<211> 632

<212> PRT

<213> Homo sapiens

<400> 2

Met	Asp	Thr	Met	Met	Leu	Asn	Val	Arg	Asn	Leu	Phe	Glu	Gln	Leu	Val	
1				5					10					15		
Arg	Arg	Val	Glu	Ile	Leu	Ser	Glu	Gly	Asn	Glu	Val	Gln	Phe	Ile	Gln	
			20					25					30			
Leu	Ala	Lys	Asp	Phe	Glu	Asp	Phe	Arg	Lys	Lys	Trp	Gln	Arg	Thr	Asp	
		35					40					45				
His	Glu	Leu	Gly	Lys	Tyr	Lys	Asp	Leu	Leu	Met	Lys	Ala	Glu	Thr	Glu	
	50					55					60					
Arg	Ser	Ala	Leu	Asp	Val	Lys	Leu	Lys	His	Ala	Arg	Asn	Gln	Val	Asp	
65					70					75					80	
Val	Glu	Ile	Lys	Arg	Arg	Gln	Arg	Ala	Glu	Ala	Asp	Cys	Glu	Lys	Leu	
				85					90					95		
Glu	Arg	Gln	Ile	Gln	Leu	Ile	Arg	Glu	Met	Leu	Met	Cys	Asp	Thr	Ser	
			100					105					110			
Gly	Ser	Ile	Gln	Leu	Ser	Glu	Glu	Gln	Lys	Ser	Ala	Leu	Ala	Phe	Leu	
	115						120					125				
Asn	Arg	Gly	Gln	Pro	Ser	Ser	Ser	Asn	Ala	Gly	Asn	Lys	Arg	Leu	Ser	
	130					135					140					
Thr	Ile	Asp	Glu	Ser	Gly	Ser	Ile	Leu	Ser	Asp	Ile	Ser	Phe	Asp	Lys	
145					150					155					160	
Thr	Asp	Glu	Ser	Leu	Asp	Trp	Asp	Ser	Ser	Leu	Val	Lys	Thr	Phe	Lys	
				165					170					175		
Leu	Lys	Lys	Arg	Glu	Lys	Arg	Arg	Ser	Thr	Ser	Arg	Gln	Phe	Val	Asp	
			180					185					190			
Gly	Pro	Pro	Gly	Pro	Val	Lys	Lys	Thr	Arg	Ser	Ile	Gly	Ser	Ala	Val	
	195						200					205				

Asp Gln Gly Asn Glu Ser Ile Val Ala Lys Thr Thr Val Thr Val Pro
 210 215 220
 Asn Asp Gly Gly Pro Ile Glu Ala Val Ser Thr Ile Glu Thr Val Pro
 225 230 235 240
 Tyr Trp Thr Arg Ser Arg Arg Lys Thr Gly Thr Leu Gln Pro Trp Asn
 245 250 255
 Ser Asp Ser Thr Leu Asn Ser Arg Gln Leu Glu Pro Arg Thr Glu Thr
 260 265 270
 Asp Ser Val Gly Thr Pro Gln Ser Asn Gly Gly Met Arg Leu His Asp
 275 280 285
 Phe Val Ser Lys Thr Val Ile Lys Pro Glu Ser Cys Val Pro Cys Gly
 290 295 300
 Lys Arg Ile Lys Phe Gly Lys Leu Ser Leu Lys Cys Arg Asp Cys Arg
 305 310 315 320
 Val Val Ser His Pro Glu Cys Arg Asp Arg Cys Pro Leu Pro Cys Ile
 325 330 335
 Pro Thr Leu Ile Gly Thr Pro Val Lys Ile Gly Glu Gly Met Leu Ala
 340 345 350
 Asp Phe Val Ser Gln Thr Ser Pro Met Ile Pro Ser Ile Val Val His
 355 360 365
 Cys Val Asn Glu Ile Glu Gln Arg Gly Leu Thr Glu Thr Gly Leu Tyr
 370 375 380
 Arg Ile Ser Gly Cys Asp Arg Thr Val Lys Glu Leu Lys Glu Lys Phe
 385 390 395 400
 Leu Arg Val Lys Thr Val Pro Leu Leu Ser Lys Val Asp Asp Ile His
 405 410 415
 Ala Ile Cys Ser Leu Leu Lys Asp Phe Leu Arg Asn Leu Lys Glu Pro
 420 425 430
 Leu Leu Thr Phe Arg Leu Asn Arg Ala Phe Met Glu Ala Ala Glu Ile
 435 440 445
 Thr Asp Glu Asp Asn Ser Ile Ala Ala Met Tyr Gln Ala Val Gly Glu
 450 455 460
 Leu Pro Gln Ala Asn Arg Asp Thr Leu Ala Phe Leu Met Ile His Leu
 465 470 475 480
 Gln Arg Val Ala Gln Ser Pro His Thr Lys Met Asp Val Ala Asn Leu
 485 490 495
 Ala Lys Val Phe Gly Pro Thr Ile Val Ala His Ala Val Pro Asn Pro
 500 505 510

Asp Pro Val Thr Met Ser Gln Asp Ile Lys Arg Gln Pro Lys Val Val
 515 520 525
 Glu Arg Leu Leu Ser Leu Pro Leu Glu Tyr Trp Ser Gln Phe Met Met
 530 535 540
 Val Glu Gln Glu Asn Ile Asp Pro Leu His Val Ile Glu Asn Ser Asn
 545 550 555 560
 Ala Phe Ser Thr Pro Gln Thr Pro Asp Ile Lys Val Ser Leu Leu Gly
 565 570 575
 Pro Val Thr Thr Pro Glu His Gln Leu Leu Lys Thr Pro Ser Ser Ser
 580 585 590
 Ser Leu Ser Gln Arg Val Arg Ser Thr Leu Thr Lys Asn Thr Pro Arg
 595 600 605
 Phe Gly Ser Lys Ser Lys Ser Ala Thr Asn Leu Gly Arg Gln Gly Asn
 610 615 620
 Phe Phe Ala Ser Pro Met Leu Lys
 625 630

<210> 3
 <211> 2919
 <212> DNA
 <213> Mus musculus

<220>
 <221> 5'UTR
 <222> (1)..(134)

<220>
 <221> CDS
 <222> (135)..(2021)

<220>
 <221> 3'UTR
 <222> (2022)..(2919)

<400> 3

ggaaagcgggt ttacactgc cgtagtgag gcgcgtcgct ggtagacagc agccctcctg 60
 gggcgcgggcg gccggagagt ggcgcgccgcg ggccggacgg ggttgcggtgt gcgcggggcc 120
 gggagcctcg aaag atg gat act aca atg gtg aat ttg tgg act ctg ttt 170
 Met Asp Thr Thr Met Val Asn Leu Trp Thr Leu Phe
 1 5 10
 gag cag ctt gtg cgc cgg atg gag att atc aat gaa gga aat gaa agc 218
 Glu Gln Leu Val Arg Arg Met Glu Ile Ile Asn Glu Gly Asn Glu Ser
 15 20 25

att gaa ttc atc cag gtt gtg aag gac ttc gag gac ttc cga aag aag	266
Ile Glu Phe Ile Gln Val Val Lys Asp Phe Glu Asp Phe Arg Lys Lys	
30 35 40	
tat caa aga acc aac cag gag ctg gag aaa ttc aaa gac cta ttg ttg	314
Tyr Gln Arg Thr Asn Gln Glu Leu Glu Lys Phe Lys Asp Leu Leu Leu	
45 50 55 60	
aaa gca gag act ggg cgg agc gcc ctg gac gtg aag ctg aag cat gcc	362
Lys Ala Glu Thr Gly Arg Ser Ala Leu Asp Val Lys Leu Lys His Ala	
65 70 75	
cgt aat caa gtg gac gtg gag atc aag cgg agg cag cgc gct gag gca	410
Arg Asn Gln Val Asp Val Glu Ile Lys Arg Arg Gln Arg Ala Glu Ala	
80 85 90	
gag tgt gca aag ctg gaa caa cag att cag ctg att cga gac ata ctc	458
Glu Cys Ala Lys Leu Glu Gln Gln Ile Gln Leu Ile Arg Asp Ile Leu	
95 100 105	
atg tgt gac aca tct ggc agt att cag ctg agt gag gaa caa aaa tca	506
Met Cys Asp Thr Ser Gly Ser Ile Gln Leu Ser Glu Glu Gln Lys Ser	
110 115 120	
gct ctc gct ttc ctc aac cga ggc caa gca tcc agt ggc cac gcc ggc	554
Ala Leu Ala Phe Leu Asn Arg Gly Gln Ala Ser Ser Gly His Ala Gly	
125 130 135 140	
aac aat aga ctg tca acg att gat gaa tct ggt tcc att tta tca gat	602
Asn Asn Arg Leu Ser Thr Ile Asp Glu Ser Gly Ser Ile Leu Ser Asp	
145 150 155	
atc agc ttt gac aag act gat gaa tca ctg gac tgg gat tct tct ttg	650
Ile Ser Phe Asp Lys Thr Asp Glu Ser Leu Asp Trp Asp Ser Ser Leu	
160 165 170	
gtg aag aat ttc aaa atg aag aaa cga gag aag agg cgc tcc aac agt	698
Val Lys Asn Phe Lys Met Lys Lys Arg Glu Lys Arg Arg Ser Asn Ser	
175 180 185	
aga cag ttc atc gac ggc cct cct ggg cct gtg aag aaa act tgt tcc	746
Arg Gln Phe Ile Asp Gly Pro Pro Gly Pro Val Lys Lys Thr Cys Ser	
190 195 200	
att ggc tct aca gta gac cag gca aat gaa tca ata gtt gca aaa act	794
Ile Gly Ser Thr Val Asp Gln Ala Asn Glu Ser Ile Val Ala Lys Thr	
205 210 215 220	
aca gtg act gtt ccc agt gat ggg gga ccc att gaa gct gtg tct act	842
Thr Val Thr Val Pro Ser Asp Gly Gly Pro Ile Glu Ala Val Ser Thr	
225 230 235	
att gag aca ttg ccg tcc tgg acc agg agt cgc ggg aag tca gga cct	890
Ile Glu Thr Leu Pro Ser Trp Thr Arg Ser Arg Gly Lys Ser Gly Pro	
240 245 250	

tta	caa	cct	gtg	aac	agt	gac	tcc	gct	ctg	aac	agc	agg	cca	ctg	gag	938
Leu	Gln	Pro	Val	Asn	Ser	Asp	Ser	Ala	Leu	Asn	Ser	Arg	Pro	Leu	Glu	
		255					260					265				
cca	aga	act	gac	aca	gac	aat	ttg	ggc	aca	cct	cag	aat	act	gga	ggc	986
Pro	Arg	Thr	Asp	Thr	Asp	Asn	Leu	Gly	Thr	Pro	Gln	Asn	Thr	Gly	Gly	
		270				275					280					
atg	cgc	ttg	cac	gac	ttc	gtc	tca	aag	acg	gtt	att	aag	cct	gaa	tct	1034
Met	Arg	Leu	His	Asp	Phe	Val	Ser	Lys	Thr	Val	Ile	Lys	Pro	Glu	Ser	
					290					295					300	
tgt	gtt	ccg	tgt	gga	aag	cgg	atc	aag	ttt	ggc	aag	ctg	tct	ctg	aag	1082
Cys	Val	Pro	Cys	Gly	Lys	Arg	Ile	Lys	Phe	Gly	Lys	Leu	Ser	Leu	Lys	
				305					310					315		
tgt	cga	gac	tgt	cgt	ttg	gtc	tcc	cat	cca	gaa	tgt	cgg	gac	cga	tgt	1130
Cys	Arg	Asp	Cys	Arg	Leu	Val	Ser	His	Pro	Glu	Cys	Arg	Asp	Arg	Cys	
			320					325					330			
ccc	ctt	ccc	tgc	atc	ccc	ccc	ctg	gtg	ggg	aca	ccg	gtt	aag	att	gga	1178
Pro	Leu	Pro	Cys	Ile	Pro	Pro	Leu	Val	Gly	Thr	Pro	Val	Lys	Ile	Gly	
		335					340					345				
gag	ggc	atg	ctg	gcc	gac	ttc	gtg	tcg	cag	gct	tct	ccc	atg	atc	cct	1226
Glu	Gly	Met	Leu	Ala	Asp	Phe	Val	Ser	Gln	Ala	Ser	Pro	Met	Ile	Pro	
		350				355					360					
gcc	att	gtc	gtc	agc	tgt	gtc	aat	gag	atc	gag	cag	cga	ggc	ctg	act	1274
Ala	Ile	Val	Val	Ser	Cys	Val	Asn	Glu	Ile	Glu	Gln	Arg	Gly	Leu	Thr	
					370					375					380	
gag	gca	ggc	ttg	tac	agg	atc	tca	ggc	tgt	gac	cgc	aca	gtg	aaa	gaa	1322
Glu	Ala	Gly	Leu	Tyr	Arg	Ile	Ser	Gly	Cys	Asp	Arg	Thr	Val	Lys	Glu	
				385				390						395		
ctg	aaa	gaa	aaa	ttc	ctt	aag	gtg	aaa	act	gtg	ccc	ctc	ctc	agc	aaa	1370
Leu	Lys	Glu	Lys	Phe	Leu	Lys	Val	Lys	Thr	Val	Pro	Leu	Leu	Ser	Lys	
			400					405				410				
gtg	gac	gat	atc	cac	gtc	atc	tgc	agc	ctc	ctg	aag	gac	ttc	ctg	cgc	1418
Val	Asp	Asp	Ile	His	Val	Ile	Cys	Ser	Leu	Leu	Lys	Asp	Phe	Leu	Arg	
		415					420					425				
aac	ctc	aaa	gag	ccc	ctc	ctg	acc	ttc	tgg	ctg	agc	aaa	gcc	ttc	atg	1466
Asn	Leu	Lys	Glu	Pro	Leu	Leu	Thr	Phe	Trp	Leu	Ser	Lys	Ala	Phe	Met	
		430				435					440					
gag	gca	gca	gag	ata	aca	gat	gaa	gac	aac	agc	aca	gcc	gcc	atg	tac	1514
Glu	Ala	Ala	Glu	Ile	Thr	Asp	Glu	Asp	Asn	Ser	Thr	Ala	Ala	Met	Tyr	
					450					455					460	
cag	gct	gtc	agt	gag	ctg	ccc	cag	gcc	aac	agg	gac	acg	cta	gcc	ttc	1562
Gln	Ala	Val	Ser	Glu	Leu	Pro	Gln	Ala	Asn	Arg	Asp	Thr	Leu	Ala	Phe	
				465					470					475		

ctt atg atc cac cta cag aga gtg tct cag agt cca gac act aag atg 1610
 Leu Met Ile His Leu Gln Arg Val Ser Gln Ser Pro Asp Thr Lys Met
 480 485 490

gat att gcc aat cta gct aaa gtc ttt ggc cct aca ata gtt gcc cat 1658
 Asp Ile Ala Asn Leu Ala Lys Val Phe Gly Pro Thr Ile Val Ala His
 495 500 505

act gtg ccc aat cca gat cca gtg aca atg ttc cag gac atc aaa cgt 1706
 Thr Val Pro Asn Pro Asp Pro Val Thr Met Phe Gln Asp Ile Lys Arg
 510 515 520

cag ctc aag gtg gtg gag cgc cta ctc tct ctc ccc ttg gag tac tgg 1754
 Gln Leu Lys Val Val Glu Arg Leu Leu Ser Leu Pro Leu Glu Tyr Trp
 525 530 535 540

aat cag ttc atg atg gtg gac caa gag aac ata gac agc cag cga ggc 1802
 Asn Gln Phe Met Met Val Asp Gln Glu Asn Ile Asp Ser Gln Arg Gly
 545 550 555

aat gga aac tca aca cca cgc aca cca gac gtt aaa gtg agc tta ctg 1850
 Asn Gly Asn Ser Thr Pro Arg Thr Pro Asp Val Lys Val Ser Leu Leu
 560 565 570

ggg cct gtg acc act cct gaa ttc cag ctt gtc aag act cct tta tca 1898
 Gly Pro Val Thr Thr Pro Glu Phe Gln Leu Val Lys Thr Pro Leu Ser
 575 580 585

agt tcc ctg tca cag agg ttg tac aac ctc tcc aag agc aca ccc aga 1946
 Ser Ser Leu Ser Gln Arg Leu Tyr Asn Leu Ser Lys Ser Thr Pro Arg
 590 595 600

ttt ggg aac aag agc aag tct gcc acc aac tta ggt caa cag ggc aaa 1994
 Phe Gly Asn Lys Ser Lys Ser Ala Thr Asn Leu Gly Gln Gln Gly Lys
 605 610 615 620

ttt ttc cct gct ccg tac ctc aag taa agctgtgtct gcctgtgttt 2041
 Phe Phe Pro Ala Pro Tyr Leu Lys
 625

actgcacgag acacccctgt ctgctcttca gcctcctgtg taatgactac ttttagcatt 2101

ttccagactt taaataaagt tgaacgcgta tgagagtttg agtgttgcat agctccctcc 2161

cacctggaca cttagcacct ttactagttg tcgggagctt taaaatagga gatctttacc 2221

agggccgaag gggaaatggg tataagttgg ggctcttagg gggaggggag aggagatccc 2281

tttggcttaa agccaaatac tgctcatgaa atgactttgc tgtggtgtca cttagacaat 2341

gacagaaact gtacctctta ggtaacgtct tagttatctc aggacaggat aaagagctgc 2401

gcagcggccc cttctcagaa cacaggcctc ttctctcttc ggggactgac aagaagcttg 2461

gagccctcag cgggatgggc cgggccactg atctgaggat gcttcacttc tgtctggggt 2521

aagctgagaa agtgccacag gctctgatct cacacagcgt gctgtttcta gccagcctct 2581

gcctggattt tgcagtcaaa gtcagggtga tctgaagccg aattcggttct gatgcctgac 2641
 ccccttgttt gtccagtgga gcccatthaa aaagtcagct agcagttcag aagacaattt 2701
 tcatatagca agaaagttag ctgcttctgt ctttggtgaa gtttttctgt gaaacagatc 2761
 tatatatgtg aacattggct tttttggtta gcattttcca gtgttcaaaa tggcttcctt 2821
 ccctgggatg ttttctgacc catactaacc cttacctgta acatgtatct ggaatattat 2881
 gtggaaaaaa taaatagctt tttcaaagtg aactttcc 2919

<210> 4

<211> 628

<212> PRT

<213> Mus musculus

<400> 4

Met	Asp	Thr	Thr	Met	Val	Asn	Leu	Trp	Thr	Leu	Phe	Glu	Gln	Leu	Val	1	5	10	15
Arg	Arg	Met	Glu	Ile	Ile	Asn	Glu	Gly	Asn	Glu	Ser	Ile	Glu	Phe	Ile	20	25	30	
Gln	Val	Val	Lys	Asp	Phe	Glu	Asp	Phe	Arg	Lys	Lys	Tyr	Gln	Arg	Thr	35	40	45	
Asn	Gln	Glu	Leu	Glu	Lys	Phe	Lys	Asp	Leu	Leu	Leu	Lys	Ala	Glu	Thr	50	55	60	
Gly	Arg	Ser	Ala	Leu	Asp	Val	Lys	Leu	Lys	His	Ala	Arg	Asn	Gln	Val	65	70	75	80
Asp	Val	Glu	Ile	Lys	Arg	Arg	Gln	Arg	Ala	Glu	Ala	Glu	Cys	Ala	Lys	85	90	95	
Leu	Glu	Gln	Gln	Ile	Gln	Leu	Ile	Arg	Asp	Ile	Leu	Met	Cys	Asp	Thr	100	105	110	
Ser	Gly	Ser	Ile	Gln	Leu	Ser	Glu	Glu	Gln	Lys	Ser	Ala	Leu	Ala	Phe	115	120	125	
Leu	Asn	Arg	Gly	Gln	Ala	Ser	Ser	Gly	His	Ala	Gly	Asn	Asn	Arg	Leu	130	135	140	
Ser	Thr	Ile	Asp	Glu	Ser	Gly	Ser	Ile	Leu	Ser	Asp	Ile	Ser	Phe	Asp	145	150	155	160
Lys	Thr	Asp	Glu	Ser	Leu	Asp	Trp	Asp	Ser	Ser	Leu	Val	Lys	Asn	Phe	165	170	175	
Lys	Met	Lys	Lys	Arg	Glu	Lys	Arg	Arg	Ser	Asn	Ser	Arg	Gln	Phe	Ile	180	185	190	

Asp Gly Pro Pro Gly Pro Val Lys Lys Thr Cys Ser Ile Gly Ser Thr
 195 200 205
 Val Asp Gln Ala Asn Glu Ser Ile Val Ala Lys Thr Thr Val Thr Val
 210 215 220
 Pro Ser Asp Gly Gly Pro Ile Glu Ala Val Ser Thr Ile Glu Thr Leu
 225 230 235 240
 Pro Ser Trp Thr Arg Ser Arg Gly Lys Ser Gly Pro Leu Gln Pro Val
 245 250 255
 Asn Ser Asp Ser Ala Leu Asn Ser Arg Pro Leu Glu Pro Arg Thr Asp
 260 265 270
 Thr Asp Asn Leu Gly Thr Pro Gln Asn Thr Gly Gly Met Arg Leu His
 275 280 285
 Asp Phe Val Ser Lys Thr Val Ile Lys Pro Glu Ser Cys Val Pro Cys
 290 295 300
 Gly Lys Arg Ile Lys Phe Gly Lys Leu Ser Leu Lys Cys Arg Asp Cys
 305 310 315 320
 Arg Leu Val Ser His Pro Glu Cys Arg Asp Arg Cys Pro Leu Pro Cys
 325 330 335
 Ile Pro Pro Leu Val Gly Thr Pro Val Lys Ile Gly Glu Gly Met Leu
 340 345 350
 Ala Asp Phe Val Ser Gln Ala Ser Pro Met Ile Pro Ala Ile Val Val
 355 360 365
 Ser Cys Val Asn Glu Ile Glu Gln Arg Gly Leu Thr Glu Ala Gly Leu
 370 375 380
 Tyr Arg Ile Ser Gly Cys Asp Arg Thr Val Lys Glu Leu Lys Glu Lys
 385 390 395 400
 Phe Leu Lys Val Lys Thr Val Pro Leu Leu Ser Lys Val Asp Asp Ile
 405 410 415
 His Val Ile Cys Ser Leu Leu Lys Asp Phe Leu Arg Asn Leu Lys Glu
 420 425 430
 Pro Leu Leu Thr Phe Trp Leu Ser Lys Ala Phe Met Glu Ala Ala Glu
 435 440 445
 Ile Thr Asp Glu Asp Asn Ser Thr Ala Ala Met Tyr Gln Ala Val Ser
 450 455 460
 Glu Leu Pro Gln Ala Asn Arg Asp Thr Leu Ala Phe Leu Met Ile His
 465 470 475 480
 Leu Gln Arg Val Ser Gln Ser Pro Asp Thr Lys Met Asp Ile Ala Asn
 485 490 495

Leu Ala Lys Val Phe Gly Pro Thr Ile Val Ala His Thr Val Pro Asn
 500 505 510
 Pro Asp Pro Val Thr Met Phe Gln Asp Ile Lys Arg Gln Leu Lys Val
 515 520 525
 Val Glu Arg Leu Leu Ser Leu Pro Leu Glu Tyr Trp Asn Gln Phe Met
 530 535 540
 Met Val Asp Gln Glu Asn Ile Asp Ser Gln Arg Gly Asn Gly Asn Ser
 545 550 555 560
 Thr Pro Arg Thr Pro Asp Val Lys Val Ser Leu Leu Gly Pro Val Thr
 565 570 575
 Thr Pro Glu Phe Gln Leu Val Lys Thr Pro Leu Ser Ser Ser Leu Ser
 580 585 590
 Gln Arg Leu Tyr Asn Leu Ser Lys Ser Thr Pro Arg Phe Gly Asn Lys
 595 600 605
 Ser Lys Ser Ala Thr Asn Leu Gly Gln Gln Gly Lys Phe Phe Pro Ala
 610 615 620
 Pro Tyr Leu Lys
 625

<210> 5
 <211> 2046
 <212> DNA
 <213> Caenorhabditis elegans

<220>
 <221> CDS
 <222> (1)..(2046)

<400> 5

atg aag tcc agt aca tca aaa gag aag gtg tgc ggc gaa aac tcg cgt	48
Met Lys Ser Ser Thr Ser Lys Glu Lys Val Cys Gly Glu Asn Ser Arg	
1 5 10 15	
cac att ttc aac atg att cta aac tca cag cga ccg caa ttc gat att	96
His Ile Phe Asn Met Ile Leu Asn Ser Gln Arg Pro Gln Phe Asp Ile	
20 25 30	
aag gat ata gga atg ttt cat ttg att gat gag att gag cgt ctc cgc	144
Lys Asp Ile Gly Met Phe His Leu Ile Asp Glu Ile Glu Arg Leu Arg	
35 40 45	
aag ctg tgg aaa gat tcc gag gaa tcc aaa aag cgg ctg aat gca gat	192
Lys Leu Trp Lys Asp Ser Glu Glu Ser Lys Lys Arg Leu Asn Ala Asp	
50 55 60	

atg aga gag gcc gaa gaa gca ctt gca aaa gct cgc aag aag ctg gca	240
Met Arg Glu Ala Glu Glu Ala Leu Ala Lys Ala Arg Lys Lys Leu Ala	
65 70 75 80	
atg ttc gat atc gat gtc aaa gac act cag aaa cat tta cgc gcg ttg	288
Met Phe Asp Ile Asp Val Lys Asp Thr Gln Lys His Leu Arg Ala Leu	
85 90 95	
atg gaa gaa aat aag gcg ttg aag ctc gat cta aac gtc tac gag act	336
Met Glu Glu Asn Lys Ala Leu Lys Leu Asp Leu Asn Val Tyr Glu Thr	
100 105 110	
cgt gaa aag cag ctg aaa gat gcg atg aag aac ggt ata ttc aat agt	384
Arg Glu Lys Gln Leu Lys Asp Ala Met Lys Asn Gly Ile Phe Asn Ser	
115 120 125	
ctc acc aag gaa gac cgc gat cag ttc aag ttt ctt cac gag cca ctg	432
Leu Thr Lys Glu Asp Arg Asp Gln Phe Lys Phe Leu His Glu Pro Leu	
130 135 140	
gtc cgg aca tac tcg aaa cgg gtg cag cag agg cat cca cat ttg atg	480
Val Arg Thr Tyr Ser Lys Arg Val Gln Gln Arg His Pro His Leu Met	
145 150 155 160	
gag gac aca cag gac gat gag gac gat agt gag gtg gat tac gat gaa	528
Glu Asp Thr Gln Asp Asp Glu Asp Asp Ser Glu Val Asp Tyr Asp Glu	
165 170 175	
act gga gac agt ttc gag gaa gtt att cat ttg cgc aat gga aga gag	576
Thr Gly Asp Ser Phe Glu Glu Val Ile His Leu Arg Asn Gly Arg Glu	
180 185 190	
gtc aga aga agc tca gct gct gga aac gca gtt ggt ggc aag cgg aga	624
Val Arg Arg Ser Ser Ala Ala Gly Asn Ala Val Gly Gly Lys Arg Arg	
195 200 205	
agc gcg tca gca cat gcg att act gct gct gcc aat tcg aag agg agc	672
Ser Ala Ser Ala His Ala Ile Thr Ala Ala Ala Asn Ser Lys Arg Ser	
210 215 220	
aga agc cgt gtt atg aca gct act ata gat gaa gag ccg aat gag ggt	720
Arg Ser Arg Val Met Thr Ala Thr Ile Asp Glu Glu Pro Asn Glu Gly	
225 230 235 240	
ggt aca cct cca aaa aga tgc cgt gat gat ggt tct aca cct cat caa	768
Gly Thr Pro Pro Lys Arg Cys Arg Asp Asp Gly Ser Thr Pro His Gln	
245 250 255	
gaa atg aca act acc acc act acc acc acc acc act act att cat aac	816
Glu Met Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Ile His Asn	
260 265 270	
tct cga gct cag aac cag gac ccg cca cgt gtc tca ctt cac cgc cag	864
Ser Arg Ala Gln Asn Gln Asp Pro Pro Arg Val Ser Leu His Arg Gln	
275 280 285	

ctc	acc	cgc	agg	agc	ttg	agc	tgt	gga	agt	att	cca	tca	tgc	gat	caa	912
Leu	Thr	Arg	Arg	Ser	Leu	Ser	Cys	Gly	Ser	Ile	Pro	Ser	Cys	Asp	Gln	
290						295					300					
aca	cca	gga	caa	acc	aca	aat	aac	atc	ggc	ctc	ggc	atg	tcg	tcc	gcc	960
Thr	Pro	Gly	Gln	Thr	Thr	Asn	Asn	Ile	Gly	Leu	Gly	Met	Ser	Ser	Ala	
305					310					315					320	
att	ctc	acc	aaa	agc	aca	ctt	gat	atc	cga	acc	ctg	aaa	cgt	ggc	acg	1008
Ile	Leu	Thr	Lys	Ser	Thr	Leu	Asp	Ile	Arg	Thr	Leu	Lys	Arg	Gly	Thr	
				325					330					335		
ccg	gcg	tgg	act	aat	gga	aca	act	cgt	gac	atc	gca	atg	aga	cca	cac	1056
Pro	Ala	Trp	Thr	Asn	Gly	Thr	Thr	Arg	Asp	Ile	Ala	Met	Arg	Pro	His	
			340					345					350			
acg	ttt	ata	gag	gca	gga	atc	aaa	gcg	atg	cga	aaa	tgc	gac	aaa	tgt	1104
Thr	Phe	Ile	Glu	Ala	Gly	Ile	Lys	Ala	Met	Arg	Lys	Cys	Asp	Lys	Cys	
		355					360					365				
gct	aca	gcc	ctg	aag	ctc	gcc	aca	tca	atg	aaa	tgc	aga	gac	tgt	cac	1152
Ala	Thr	Ala	Leu	Lys	Leu	Ala	Thr	Ser	Met	Lys	Cys	Arg	Asp	Cys	His	
	370					375					380					
cag	gtt	gtc	cat	cgt	agt	tgc	tgc	aac	aaa	ctt	cat	ctc	ccg	tgc	ata	1200
Gln	Val	Val	His	Arg	Ser	Cys	Cys	Asn	Lys	Leu	His	Leu	Pro	Cys	Ile	
385					390					395					400	
cca	cgc	ccc	aag	acg	atg	atg	acg	ccg	aaa	tcc	gca	tta	cgt	gga	gcc	1248
Pro	Arg	Pro	Lys	Thr	Met	Met	Thr	Pro	Lys	Ser	Ala	Leu	Arg	Gly	Ala	
				405					410					415		
aag	ccg	ggc	gca	gga	gag	ttc	cga	ctt	caa	gat	ttg	tgc	aca	tct	gcg	1296
Lys	Pro	Gly	Ala	Gly	Glu	Phe	Arg	Leu	Gln	Asp	Leu	Cys	Thr	Ser	Ala	
			420					425					430			
aag	cca	atg	atc	ccg	gca	gca	gtt	att	cat	tgt	gtg	gtt	gcc	ctg	gag	1344
Lys	Pro	Met	Ile	Pro	Ala	Ala	Val	Ile	His	Cys	Val	Val	Ala	Leu	Glu	
			435				440						445			
gct	cgt	gga	ctc	acg	cag	gaa	ggc	att	tac	cgc	gtt	cct	ggg	cag	gtt	1392
Ala	Arg	Gly	Leu	Thr	Gln	Glu	Gly	Ile	Tyr	Arg	Val	Pro	Gly	Gln	Val	
	450					455					460					
aga	act	gtc	aat	gtg	ctt	ttg	gac	gag	ttg	aga	tca	aaa	acg	gta	ccc	1440
Arg	Thr	Val	Asn	Val	Leu	Leu	Asp	Glu	Leu	Arg	Ser	Lys	Thr	Val	Pro	
	465				470					475					480	
aac	gtg	ggc	ctt	cac	gac	gtt	gag	gtc	atc	aca	gac	acc	ttg	aaa	cgg	1488
Asn	Val	Gly	Leu	His	Asp	Val	Glu	Val	Ile	Thr	Asp	Thr	Leu	Lys	Arg	
				485					490					495		
ttc	cta	aga	gat	ctt	aaa	gac	ccg	ttg	atc	cca	aga	acg	tct	cgt	caa	1536
Phe	Leu	Arg	Asp	Leu	Lys	Asp	Pro	Leu	Ile	Pro	Arg	Thr	Ser	Arg	Gln	
			500					505					510			

gag ctc atc gtt gct gca aac ctc tac tct acg gat cca gat aat gga 1584
 Glu Leu Ile Val Ala Ala Asn Leu Tyr Ser Thr Asp Pro Asp Asn Gly
 515 520 525

cgt ctc gcc ctg aat cga gtg atc tgt gag ctc ccc caa gcg aat cga 1632
 Arg Leu Ala Leu Asn Arg Val Ile Cys Glu Leu Pro Gln Ala Asn Arg
 530 535 540

gac acc ctc gcc tac ctt ttc att cac tgg cgc aaa gtt atc gca caa 1680
 Asp Thr Leu Ala Tyr Leu Phe Ile His Trp Arg Lys Val Ile Ala Gln
 545 550 555 560

tcg agt cgc aac aag atg aac tgc gaa gcg atg gcg cgg atg gtg gct 1728
 Ser Ser Arg Asn Lys Met Asn Cys Glu Ala Met Ala Arg Met Val Ala
 565 570 575

ccg gcg gtg atg ggt cat cca gtg aag caa tcg cag tcc caa gcg ata 1776
 Pro Ala Val Met Gly His Pro Val Lys Gln Ser Gln Ser Gln Ala Ile
 580 585 590

gct ggc aga gat gcc acg gat tgc cat cga gcg atg act gct cta ttt 1824
 Ala Gly Arg Asp Ala Thr Asp Cys His Arg Ala Met Thr Ala Leu Phe
 595 600 605

gaa ttt gat gat gta tat tgg caa cga ttc cta ggg aca tct gca gtt 1872
 Glu Phe Asp Asp Val Tyr Trp Gln Arg Phe Leu Gly Thr Ser Ala Val
 610 615 620

tcc atg gct tct aat caa att gaa acg gct cga cat cag gac aat ttt 1920
 Ser Met Ala Ser Asn Gln Ile Glu Thr Ala Arg His Gln Asp Asn Phe
 625 630 635 640

gct ctc tgt gat cgt agc atc ctt gga cca gtt aca aca tca cca gcc 1968
 Ala Leu Cys Asp Arg Ser Ile Leu Gly Pro Val Thr Thr Ser Pro Ala
 645 650 655

act ccc ctg ctt gct cgg tcg gcc aac gcg act cga gca cgt ggt gct 2016
 Thr Pro Leu Leu Ala Arg Ser Ala Asn Ala Thr Arg Ala Arg Gly Ala
 660 665 670

cat ctg ctg ggg tcg atg ttc cac gat tag 2046
 His Leu Leu Gly Ser Met Phe His Asp
 675 680

<210> 6

<211> 681

<212> PRT

<213> Caenorhabditis elegans

<400> 6

Met Lys Ser Ser Thr Ser Lys Glu Lys Val Cys Gly Glu Asn Ser Arg
 1 5 10 15

His Ile Phe Asn Met Ile Leu Asn Ser Gln Arg Pro Gln Phe Asp Ile
 20 25 30

Lys Asp Ile Gly Met Phe His Leu Ile Asp Glu Ile Glu Arg Leu Arg
 35 40 45
 Lys Leu Trp Lys Asp Ser Glu Glu Ser Lys Lys Arg Leu Asn Ala Asp
 50 55 60
 Met Arg Glu Ala Glu Glu Ala Leu Ala Lys Ala Arg Lys Lys Leu Ala
 65 70 75 80
 Met Phe Asp Ile Asp Val Lys Asp Thr Gln Lys His Leu Arg Ala Leu
 85 90 95
 Met Glu Glu Asn Lys Ala Leu Lys Leu Asp Leu Asn Val Tyr Glu Thr
 100 105 110
 Arg Glu Lys Gln Leu Lys Asp Ala Met Lys Asn Gly Ile Phe Asn Ser
 115 120 125
 Leu Thr Lys Glu Asp Arg Asp Gln Phe Lys Phe Leu His Glu Pro Leu
 130 135 140
 Val Arg Thr Tyr Ser Lys Arg Val Gln Gln Arg His Pro His Leu Met
 145 150 155 160
 Glu Asp Thr Gln Asp Asp Glu Asp Asp Ser Glu Val Asp Tyr Asp Glu
 165 170 175
 Thr Gly Asp Ser Phe Glu Glu Val Ile His Leu Arg Asn Gly Arg Glu
 180 185 190
 Val Arg Arg Ser Ser Ala Ala Gly Asn Ala Val Gly Gly Lys Arg Arg
 195 200 205
 Ser Ala Ser Ala His Ala Ile Thr Ala Ala Ala Asn Ser Lys Arg Ser
 210 215 220
 Arg Ser Arg Val Met Thr Ala Thr Ile Asp Glu Glu Pro Asn Glu Gly
 225 230 235 240
 Gly Thr Pro Pro Lys Arg Cys Arg Asp Asp Gly Ser Thr Pro His Gln
 245 250 255
 Glu Met Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Ile His Asn
 260 265 270
 Ser Arg Ala Gln Asn Gln Asp Pro Pro Arg Val Ser Leu His Arg Gln
 275 280 285
 Leu Thr Arg Arg Ser Leu Ser Cys Gly Ser Ile Pro Ser Cys Asp Gln
 290 295 300
 Thr Pro Gly Gln Thr Thr Asn Asn Ile Gly Leu Gly Met Ser Ser Ala
 305 310 315 320
 Ile Leu Thr Lys Ser Thr Leu Asp Ile Arg Thr Leu Lys Arg Gly Thr
 325 330 335

Pro Ala Trp Thr Asn Gly Thr Thr Arg Asp Ile Ala Met Arg Pro His
 340 345 350
 Thr Phe Ile Glu Ala Gly Ile Lys Ala Met Arg Lys Cys Asp Lys Cys
 355 360 365
 Ala Thr Ala Leu Lys Leu Ala Thr Ser Met Lys Cys Arg Asp Cys His
 370 375 380
 Gln Val Val His Arg Ser Cys Cys Asn Lys Leu His Leu Pro Cys Ile
 385 390 395 400
 Pro Arg Pro Lys Thr Met Met Thr Pro Lys Ser Ala Leu Arg Gly Ala
 405 410 415
 Lys Pro Gly Ala Gly Glu Phe Arg Leu Gln Asp Leu Cys Thr Ser Ala
 420 425 430
 Lys Pro Met Ile Pro Ala Ala Val Ile His Cys Val Val Ala Leu Glu
 435 440 445
 Ala Arg Gly Leu Thr Gln Glu Gly Ile Tyr Arg Val Pro Gly Gln Val
 450 455 460
 Arg Thr Val Asn Val Leu Leu Asp Glu Leu Arg Ser Lys Thr Val Pro
 465 470 475 480
 Asn Val Gly Leu His Asp Val Glu Val Ile Thr Asp Thr Leu Lys Arg
 485 490 495
 Phe Leu Arg Asp Leu Lys Asp Pro Leu Ile Pro Arg Thr Ser Arg Gln
 500 505 510
 Glu Leu Ile Val Ala Ala Asn Leu Tyr Ser Thr Asp Pro Asp Asn Gly
 515 520 525
 Arg Leu Ala Leu Asn Arg Val Ile Cys Glu Leu Pro Gln Ala Asn Arg
 530 535 540
 Asp Thr Leu Ala Tyr Leu Phe Ile His Trp Arg Lys Val Ile Ala Gln
 545 550 555 560
 Ser Ser Arg Asn Lys Met Asn Cys Glu Ala Met Ala Arg Met Val Ala
 565 570 575
 Pro Ala Val Met Gly His Pro Val Lys Gln Ser Gln Ser Gln Ala Ile
 580 585 590
 Ala Gly Arg Asp Ala Thr Asp Cys His Arg Ala Met Thr Ala Leu Phe
 595 600 605
 Glu Phe Asp Asp Val Tyr Trp Gln Arg Phe Leu Gly Thr Ser Ala Val
 610 615 620
 Ser Met Ala Ser Asn Gln Ile Glu Thr Ala Arg His Gln Asp Asn Phe
 625 630 635 640

Ala Leu Cys Asp Arg Ser Ile Leu Gly Pro Val Thr Thr Ser Pro Ala
645 650 655

Thr Pro Leu Leu Ala Arg Ser Ala Asn Ala Thr Arg Ala Arg Gly Ala
660 665 670

His Leu Leu Gly Ser Met Phe His Asp
675 680